var title_f15_22_15712="Tinea versicolor chest 2";
var content_f15_22_15712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea versicolor chest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperpigmented macules and patches are present on the chest in this patient with tinea versicolor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Paul S Matz, MD. Reproduced from: Chung EK, Boom JA, Datto GA, Matz PS (Eds). Visual Diagnosis in Pediatrics. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15712=[""].join("\n");
var outline_f15_22_15712=null;
var title_f15_22_15713="Patient information: Acute interstitial nephritis (The Basics)";
var content_f15_22_15713=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83997\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?6/56/7053\">",
"         Medicines that can cause acute interstitial nephritis",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Acute interstitial nephritis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/acute-interstitial-nephritis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6716280\">",
"      <span class=\"h1\">",
"       What is acute interstitial nephritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Acute interstitial nephritis is a rare condition that causes inflammation of the kidneys. Most of the time, it is caused by a reaction to certain medicines. These include medicines that treat pain, infections, and other conditions (",
"      <a class=\"graphic graphic_table graphicRef83922 \" href=\"UTD.htm?6/56/7053\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Diseases that involve the body&rsquo;s infection-fighting system (called &ldquo;autoimmune diseases&rdquo;) and infections can also cause acute interstitial nephritis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6716295\">",
"      <span class=\"h1\">",
"       What are the symptoms of acute interstitial nephritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people have no symptoms. But symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Feeling sick to your stomach (nausea)",
"       </li>",
"       <li>",
"        Throwing up (vomiting)",
"       </li>",
"       <li>",
"        Feeling very tired",
"       </li>",
"       <li>",
"        Rash &ndash; This looks like small, flat red bumps and can happen anywhere on the body.",
"       </li>",
"       <li>",
"        Urine that looks cloudy or red",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6716310\">",
"      <span class=\"h1\">",
"       Are there tests for acute interstitial nephritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, a doctor might do a kidney &ldquo;biopsy.&rdquo; For this test, the doctor takes a small sample of tissue from your kidney to look at under the microscope. Usually, the doctor will get this sample by inserting a needle straight through the skin in the back and into the kidney.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6716325\">",
"      <span class=\"h1\">",
"       How is acute interstitial nephritis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people get better after they stop the medicine that caused the condition. Some people also take medicines called steroids. These medicines help reduce inflammation. They are not the same as the steroids athletes use to build muscle.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6716340\">",
"      <span class=\"h1\">",
"       Can acute interstitial nephritis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people who take the medicines that can cause acute interstitial nephritis do NOT get it. But if you have had acute interstitial nephritis in the past, you can reduce your chances of getting it again by avoiding the medicine that caused it the first time.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?15/22/15713?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83997 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15713=[""].join("\n");
var outline_f15_22_15713=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6716280\">",
"      What is acute interstitial nephritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6716295\">",
"      What are the symptoms of acute interstitial nephritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6716310\">",
"      Are there tests for acute interstitial nephritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6716325\">",
"      How is acute interstitial nephritis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6716340\">",
"      Can acute interstitial nephritis be prevented?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83997\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/56/7053\">",
"      Medicines that can cause acute interstitial nephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_22_15714="Nevus central hyperpigmentation";
var content_f15_22_15714=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermoscopic image of a nevus with a peripheral reticular and central hyperpigmented pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15714=[""].join("\n");
var outline_f15_22_15714=null;
var title_f15_22_15715="LIFT";
var content_f15_22_15715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ligation of the intersphincteric fistula tract (LIFT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This intra-operative photograph shows the probe inserted into the secondary external opening and extending into the internal primary opening of the fistula tract.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of R Kumar, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15715=[""].join("\n");
var outline_f15_22_15715=null;
var title_f15_22_15716="Evaluating nutritional support for moderate to severe burn patients";
var content_f15_22_15716=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluating nutritional support for moderate to severe burn patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/22/15716/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15716/contributors\">",
"     Amalia Cochran, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/22/15716/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15716/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/22/15716/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15716/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/22/15716/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional support represents one of the most important cornerstones in the management of patients with a moderate to severe burn injury. Clinical monitoring is the key tool for assessment of the adequacy of nutritional support. Laboratory markers for immune response, indirect calorimetry, and body weight and composition are also used.",
"   </p>",
"   <p>",
"    This topic reviews assessment of the adequacy of nutritional support in burn patients. Patient selection, timing, delivery, and types of nutrition support, calculating caloric requirements for burn patients and selection of enteral formula are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=see_link\">",
"     \"Overview of nutritional support for moderate to severe burn patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11401?source=see_link\">",
"     \"Nutritional demands and enteral formulas for moderate to severe burn patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MONITORING TOOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adequacy of nutritional support is monitored by assessing the patient's clinical course and wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/1\">",
"     1",
"    </a>",
"    ]. Trends, rather than single measurements or point estimates, should be monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parameters used to evaluate the clinical course include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemodynamic stability",
"     </li>",
"     <li>",
"      Respiratory status",
"     </li>",
"     <li>",
"      Functional status",
"     </li>",
"     <li>",
"      Evidence of infection or sepsis",
"     </li>",
"     <li>",
"      Tolerating diet",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Wound healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;An experienced clinician should evaluate the patient's burns daily. Assessment of the wound includes recording size, depth, condition of the base, and pain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/2\">",
"     2",
"    </a>",
"    ]. This examination allows for early identification of delayed or inadequate wound healing, both of which are markers of nutritional deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TOTAL BODY WEIGHT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total body weight (TBW) measures two components: lean weight (muscles, bones, tendons, ligaments, and water) and fat weight. While measurements of TBW are helpful in evaluating nutritional status in healthy individuals, the significant volume of fluid required for resuscitation in burn patients limits its value to assess nutritional status, particularly during the acute phase of burn care. The daily measurement of TBW is used in the majority of burn centers in the United States as one indicator for monitoring and evaluating nutritional status [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/5\">",
"     5",
"    </a>",
"    ]. Long-term trends in TBW are a helpful indicator of nutritional status when patients enter the rehabilitative phase of burn care [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LEAN BODY MASS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of lean body mass (LBM) represents one of the central tenets of nutritional support in burn patients. LBM theoretically can be monitored using body composition technology such as total body potassium counting (K-counter), dual X-ray absorptiometry (DEXA) scanning, and bioimpedance analysis (BIA).",
"   </p>",
"   <p>",
"    We do not use any of these technologies, as further studies are needed to determine the utility and appropriateness of routine use in the burn care setting. No studies of BIA have been published in burn patients, though the bedside nature of BIA makes it convenient as a routine clinical tool. Both K-counter and DEXA have been routinely used in long-term studies of pediatric burn patients, but have not been used as a routine component for evaluating clinical nutrition status [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Body composition assessment by current techniques cannot be reliably used as a means to monitor nutritional status in burn patients because of the edema and fluid shifts associated with the inflammatory response to the burn injury [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INDIRECT CALORIMETRY ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indirect calorimetry (IDC) can be used to determine the nutritional requirements, as well as serve as an indicator of response to nutritional support, particularly in the difficult to manage patient [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11401?source=see_link&amp;anchor=H2#H2\">",
"     \"Nutritional demands and enteral formulas for moderate to severe burn patients\", section on 'Determining caloric requirements'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of IDC is controversial, particularly as a single measurement point [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. One of the greatest limitations of IDC is that energy expenditure fluctuates with activity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/7\">",
"     7",
"    </a>",
"    ]. We recommend using trends in IDC as a more reliable estimate of adequate nutritional support than a single measurement. IDC is monitored twice per week in our burn center, with adjustments in nutritional support occurring no more than twice per week based upon trends in IDC, nitrogen balance data, and clinical progress. Two-thirds of responding burn center dieticians indicated that they used IDC to assess energy demands in adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NITROGEN BALANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of adequate nutritional support must address both energy requirements and protein demands of burn patients. Nitrogen balance, therefore, plays an important role in assessing nutritional adequacy following burn injury. Measuring urinary urea nitrogen (UUN) and calculating nitrogen balance on a weekly basis allows approximation of the trend in nitrogen breakdown and appropriate adjustment of protein goals, particularly when used in conjunction with the previously described methods of nutrition status monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/7,14\">",
"     7,14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical monitoring tools'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In children with severe burns, UUN is imprecise, reflecting the diminished reliability of UUN measurements in patients with hypercatabolic responses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LABORATORY TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic changes that accompany a burn injury make it difficult to accurately interpret laboratory markers. The practice at our burn center is to not use visceral proteins (eg, albumin) to monitor nutritional status, as our experience with them has been unreliable. Furthermore, while there are markers that correlate with compromised nutritional status, they do not provide a meaningful measure of overall trends in nutritional status for burn patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serum albumin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum albumin does not correlate with nitrogen balance in burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/6\">",
"     6",
"    </a>",
"    ]. Serum albumin levels decrease dramatically with injury and remain chronically depressed following burns, even when other indicators suggest adequate nutritional support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inflammatory response proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not monitor the adequacy of nutritional support with transthyretin, transferrin, retinol-binding protein, and C-reactive protein during the convalescent phase. If these protein markers are monitored, we suggest that they be used only in conjunction with the assessment of the clinical course and wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/6,7,14,16\">",
"     6,7,14,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transthyretin (prealbumin), C-reactive protein, retinol-binding protein, and transferrin have all been considered as laboratory markers for assessing the efficacy of nutritional support in burn patients. Transthyretin, like albumin, decreases dramatically following burn injury, although it gradually recovers with adequate nutrition and as the inflammatory response subsides. There is a positive association with transthyretin level and wound healing and an extremely weak association with nitrogen balance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. In a cross-sectional study of 50 burn patients, transthyretin was the factor significantly associated with graft healing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/17\">",
"     17",
"    </a>",
"    ]. Transthyretin levels that do not improve with adequate nutrition and a normalizing C-reactive protein may be indicative of either a protein or calorie deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/7\">",
"     7",
"    </a>",
"    ]. Retinol-binding protein and transferrin failed to demonstrate a meaningful correlation with nitrogen balance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15716/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional support represents one of the most important cornerstones in the management of patients with a moderate to severe burn injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The adequacy of nutritional support is best assessed by the clinical course and wound healing. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical monitoring tools'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When used in conjunction with daily clinical assessment, evaluating trends in total body weight, indirect calorimetry, and laboratory results can be helpful in assessing adequacy of nutritional support. Single random measurements are not useful. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical monitoring tools'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most burn centers measure total body weight (TBW) daily. The long-term trend in TBW is a helpful indicator of nutritional status when patients enter the rehabilitative phase of burn care. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Total body weight'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maintenance of lean body mass (LBM) is one of the central tenets of nutritional support in burn patients, but there is no proven method for accurate assessment of LBM. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lean body mass'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We make adjustments in nutritional support no more than twice per week based upon trends in indirect calorimetry, urinary urea nitrogen, and clinical progress. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indirect calorimetry assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Nitrogen balance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory tests are difficult to accurately interpret following a burn injury. If laboratory tests are used to assess nutritional status, they should be used in conjunction with the assessment of the clinical course and wound healing. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Saffle, JR, Graves, C. Nutritional support of the burned patient. In: Total Burn Care: 3rd Edition, Herndon, DN (Ed), Saunders Elsevier, Philadelphia, PA 2007. p.398.",
"    </li>",
"    <li>",
"     Fette, AM. A clinimetric analysis of wound measurement tools. Available online at: www.worldwidewounds.com (Accessed on March 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/3\">",
"      Berger MM. Vitamin C requirements in parenteral nutrition. Gastroenterology 2009; 137:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/4\">",
"      Albina JE. Nutrition and wound healing. JPEN J Parenter Enteral Nutr 1994; 18:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/5\">",
"      Graves C, Saffle J, Cochran A. Actual burn nutrition care practices: an update. J Burn Care Res 2009; 30:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/6\">",
"      Carlson DE, Cioffi WG Jr, Mason AD Jr, et al. Evaluation of serum visceral protein levels as indicators of nitrogen balance in thermally injured patients. JPEN J Parenter Enteral Nutr 1991; 15:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/7\">",
"      Prelack K, Dylewski M, Sheridan RL. Practical guidelines for nutritional management of burn injury and recovery. Burns 2007; 33:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/8\">",
"      Hart DW, Wolf SE, Herndon DN, et al. Energy expenditure and caloric balance after burn: increased feeding leads to fat rather than lean mass accretion. Ann Surg 2002; 235:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/9\">",
"      Branski LK, Norbury WB, Herndon DN, et al. Measurement of body composition in burned children: is there a gold standard? JPEN J Parenter Enteral Nutr 2010; 34:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/10\">",
"      Przkora R, Barrow RE, Jeschke MG, et al. Body composition changes with time in pediatric burn patients. J Trauma 2006; 60:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/11\">",
"      Boullata J, Williams J, Cottrell F, et al. Accurate determination of energy needs in hospitalized patients. J Am Diet Assoc 2007; 107:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/12\">",
"      Liusuwan RA, Palmieri TL, Kinoshita L, Greenhalgh DG. Comparison of measured resting energy expenditure versus predictive equations in pediatric burn patients. J Burn Care Rehabil 2005; 26:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/13\">",
"      Liusuwan Manotok RA, Palmieri TL, Greenhalgh DG. The respiratory quotient has little value in evaluating the state of feeding in burn patients. J Burn Care Res 2008; 29:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/14\">",
"      Dickerson RN. Estimating energy and protein requirements of thermally injured patients: art or science? Nutrition 2002; 18:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/15\">",
"      Prelack K, Dwyer J, Yu YM, et al. Urinary urea nitrogen is imprecise as a predictor of protein balance in burned children. J Am Diet Assoc 1997; 97:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/16\">",
"      Mayes T, Gottschlich MM, Warden GD. Clinical nutrition protocols for continuous quality improvements in the outcomes of patients with burns. J Burn Care Rehabil 1997; 18:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15716/abstract/17\">",
"      Moghazy AM, Adly OA, Abbas AH, et al. Assessment of the relation between prealbumin serum level and healing of skin-grafted burn wounds. Burns 2010; 36:495.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 817 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15716=[""].join("\n");
var outline_f15_22_15716=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MONITORING TOOLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Wound healing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TOTAL BODY WEIGHT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LEAN BODY MASS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INDIRECT CALORIMETRY ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NITROGEN BALANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LABORATORY TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serum albumin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inflammatory response proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11401?source=related_link\">",
"      Nutritional demands and enteral formulas for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=related_link\">",
"      Overview of nutritional support for moderate to severe burn patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_22_15717="Flucytosine: Patient drug information";
var content_f15_22_15717=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Flucytosine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     see \"Flucytosine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/46/27365?source=see_link\">",
"     see \"Flucytosine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ancobon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor must closely watch your blood cells and kidney and liver function.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk to your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bad yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702131",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to flucytosine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695906",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop upset stomach. Take a few capsules at a time over 15 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature or in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699608",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of liquid not used and stored at room temperature after 2 weeks or after 2 months when stored in a refrigerator.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12476 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15717=[""].join("\n");
var outline_f15_22_15717=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171786\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027536\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027538\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027537\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027542\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027543\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027545\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027540\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027541\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027546\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027547\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=related_link\">",
"      Flucytosine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/46/27365?source=related_link\">",
"      Flucytosine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_22_15718="Atrophie blanche lipodermatosclerosis 1";
var content_f15_22_15718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Atrophie blanche",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrophie blanche in a patient with lipodermatosclerosis: characteristic ivory-white, stellate fibrotic scars.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15718=[""].join("\n");
var outline_f15_22_15718=null;
var title_f15_22_15719="Female pattern hair loss 2";
var content_f15_22_15719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Female pattern hair loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A marked reduction in terminal hair density is present on the crown of the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15719=[""].join("\n");
var outline_f15_22_15719=null;
var title_f15_22_15720="Ovarian development and failure (menopause) in normal women";
var content_f15_22_15720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ovarian development and failure (menopause) in normal women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/22/15720/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15720/contributors\">",
"     Corrine K Welt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/22/15720/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15720/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15720/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/22/15720/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15720/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/22/15720/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review the basic aspects of ovarian development and the pathogenesis and epidemiology of menopause. The clinical manifestations, diagnosis, and management of menopause are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVARIAN DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three main steps in ovarian development: germ cell differentiation, continuous follicular growth, and continuous follicular atresia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Germ cell differentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the first events of sexual differentiation, occurring as early as the two cell stage of the zygote, is the random, nearly complete inactivation of one X chromosome in all female somatic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/1\">",
"     1",
"    </a>",
"    ], but not germ cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, somatic cells have only a few active X chromosome genes, whereas germ cells have two complete X chromosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primordial undifferentiated germ cells then migrate during the fourth to eighth weeks of gestation from the yolk sac to the gonadal ridge, where they are required for development of the ovaries [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/3\">",
"     3",
"    </a>",
"    ]. In the absence of a testicular differentiation factor from the Y chromosome, which directs the production of M&uuml;llerian inhibiting substance (MIS) by four to six weeks gestation in males [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/4\">",
"     4",
"    </a>",
"    ], the germ cells differentiate into primitive oogonia, which begin mitosis at about six weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=see_link\">",
"     \"Normal sexual differentiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A quantitative morphologic study of germ cells in 17 normal human fetuses revealed a maximum of seven million germ cells five months after conception [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/3\">",
"     3",
"    </a>",
"    ]; this small study remains the basis of most of our current understanding of oogenesis in humans. The first meiotic division is initiated at about 15 weeks, signaling the transformation of oogonia to oocytes. This meiotic division is then arrested at the first prophase until primordial follicles are formed. Medullary structures infiltrate the ovarian cortex and surround the oocytes to invest each one with a single layer of primordial granulosa cells at about 20 weeks of gestation, thereby beginning the formation of primordial follicles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Continuous follicular growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular and ovarian growth have been studied in late gestational fetuses and prepubertal children, using autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/3\">",
"     3",
"    </a>",
"    ], laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/5\">",
"     5",
"    </a>",
"    ], and ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/6\">",
"     6",
"    </a>",
"    ]. Follicular growth is initiated in the fetus in a continuous pattern that is independent of gonadotropins and is apparently related to both the total mass of follicles and to factors released by atretic follicles [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Follicles are capable of growth up to the pre-antral (pre-luminal) stage in the absence of gonadotropins, based upon studies of girls with congenital deficiency of gonadotropin-releasing hormone (GnRH) (Kallmann syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/9\">",
"     9",
"    </a>",
"    ] and anencephalic fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link\">",
"     \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further follicular development requires follicle-stimulating hormone (FSH) stimulation of granulosa cells and induction of luteinizing hormone (LH) receptors, and therefore responsiveness to LH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/11\">",
"     11",
"    </a>",
"    ], leading to formation of preovulatory follicles and then to ovulation and formation of the corpus luteum. The ovaries of normal human fetuses, infants, and prepubertal children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/12-14\">",
"     12-14",
"    </a>",
"    ] contain larger antral follicles. These follicles are probably formed in response to low levels of pulsatile FSH and LH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/14\">",
"     14",
"    </a>",
"    ], based upon studies using very sensitive gonadotropin assays [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Continuous follicular atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As soon as primordial follicles are formed in the fetus, before there is detectable follicular responsiveness to FSH, inexorable cycles of follicular growth and subsequent atresia begin. These cycles result in an exponential fall in oocyte number even",
"    <strong>",
"     before birth",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    The atresia is a poorly understood process of follicular degradation. It can apparently occur at any point during follicular growth and development, and may be associated with reinitiation of meiosis. Studies in both animals and humans suggest that apoptosis is the mechanism responsible for oocyte depletion and follicular atresia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suppression of granulosa-cell division by decreasing gonadotropin stimulation can cause atresia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/8\">",
"       8",
"      </a>",
"      ], whether achieved by decreasing FSH secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/18\">",
"       18",
"      </a>",
"      ] or blocking of FSH action.",
"     </li>",
"     <li>",
"      Once a follicle reaches the preovulatory stage, inhibition of theca-cell function can cause atresia by blocking production of the androgen precursors necessary for subsequent aromatization to estrogens during the final stages of follicle differentiation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In young girls, most if not all follicles that reach the pre-antral (1 mm) stage are already atretic, and the rate of atresia is increased in larger follicles [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is evidence that human and porcine follicular cells produce a meiosis-inhibiting factor that may arrest atresia by inhibiting the progression of meiosis in oocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. MIS is produced in fetal ovaries and may have a role in regulating meiosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/22-24\">",
"       22-24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a mouse model, Bax and bcl-2, genes expressed in both oocytes and granulosa cells, may play a central role in follicular atresia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. In a Bax knockout mouse, ovarian lifespan is prolonged when compared with wild-type controls. In contrast, in a bcl-2 knockout mouse, the number of primordial follicles is reduced.",
"     </li>",
"     <li>",
"      Follicular depletion in the human fetus may be primarily due to apoptosis of oocytes, while in adult life granulosa cell apoptosis may play an important role in follicular demise [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the evidence that the ovary contains a finite number of oocytes that are lost at a steady rate until menopause, a 2004 study of adult mice reported that new oocyte-containing follicles, presumably from stem cells, continue to develop [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/28\">",
"     28",
"    </a>",
"    ]. In a follow-up report by the same investigators, the bone marrow was identified as the possible source of the germline stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/29\">",
"     29",
"    </a>",
"    ]. However, other investigators have reported that bone marrow cells do",
"    <strong>",
"     not",
"    </strong>",
"    contribute to the formation of mature, ovulated oocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2009 report, female germline stem cells were isolated from neonatal mice and transplanted into sterile adult mice, who then were able to produce offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/31\">",
"     31",
"    </a>",
"    ]. In a second study, oogonial stem cells were isolated from neonatal and adult mouse ovaries; pups were subsequently born from the oocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/31\">",
"     31",
"    </a>",
"    ]. Further experiments are needed before the implications for humans can be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OVARIAN FUNCTION DURING THE REPRODUCTIVE YEARS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful autopsy studies of small numbers of women who died prematurely revealed a steady exponential decline in oocyte number throughout early adult life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/3,32,33\">",
"     3,32,33",
"    </a>",
"    ]; however, only small numbers of older women have been studied (",
"    <a class=\"graphic graphic_figure graphicRef72948 \" href=\"UTD.htm?15/43/16062\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Thus, there is uncertainty about the rate of decline in oocyte numbers during these years.",
"   </p>",
"   <p>",
"    A study evaluated the menstrual cycles, serum hormone concentrations, and oocyte viability in young women and older women who were still having regular menstrual cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/36\">",
"     36",
"    </a>",
"    ]. Oocyte viability declined in older women before they had any measurable decrease in serum or intrafollicular hormone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/36\">",
"     36",
"    </a>",
"    ]. These results may explain the gradual decrease in fecundity after age 30 to 35 years in normal women (",
"    <a class=\"graphic graphic_figure graphicRef80807 \" href=\"UTD.htm?18/58/19375\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/37\">",
"     37",
"    </a>",
"    ]. The isolated increases in serum FSH concentrations that are found in some normally cycling older women are probably caused by decreasing ovarian production of inhibin&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef77945 \" href=\"UTD.htm?30/53/31583\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MENOPAUSAL YEARS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menopause occurs at a mean age of 51 years in normal women in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    .) It is associated with a marked decline in oocyte number that is attributable to progressive atresia of the original complement of oocytes (",
"    <a class=\"graphic graphic_figure graphicRef72948 \" href=\"UTD.htm?15/43/16062\">",
"     figure 1",
"    </a>",
"    ). However, the evidence for absolute oocyte depletion at this time is limited. Residual oocytes and differentiating follicles have been identified in the ovaries of some postmenopausal women, although the follicles are frequently atretic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decrease in developing follicles is reflected in a parallel decrease in the serum concentration of inhibin B, which is probably the earliest easily measurable marker of follicular decline (",
"    <a class=\"graphic graphic_figure graphicRef77945 \" href=\"UTD.htm?30/53/31583\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The rise in the serum concentration of FSH in early menopause is also closely related to the fall in inhibin B; this suggests that inhibin B plays an important role in the normal control of FSH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum concentrations of MIS (also known as anti-m&uuml;llerian hormone [AMH]) may be a useful marker reflecting reproductive aging [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Low serum AMH concentrations were predictive of a poor ovarian response to exogenous gonadotropin stimulation and may mark a critical juncture in the timing of the menopausal transition [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Menopausal transition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the progressive decline in ovarian function results in cycle disruption, the normal menopausal transition (also known as perimenopause) can last for several years. Waxing and waning of ovarian function is common.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the early menopausal transition, women begin to experience some menstrual irregularity (",
"      <a class=\"graphic graphic_figure graphicRef82933 \" href=\"UTD.htm?34/59/35760\">",
"       figure 4",
"      </a>",
"      ). As noted above, inhibin B and AMH concentrations fall due to a decline in follicular number and, as a result, serum FSH levels begin to rise, with relative preservation of estradiol secretion (normal or high estradiol levels), but with low luteal phase progesterone concentrations (",
"      <a class=\"graphic graphic_figure graphicRef77945 \" href=\"UTD.htm?30/53/31583\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef79769 \" href=\"UTD.htm?35/16/36111\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/40-42,48,49\">",
"       40-42,48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the late menopausal transition, cycle variability increases. In addition, fluctuations in serum concentrations of FSH and estradiol may be quite striking; high FSH and low estradiol values may be suggestive of menopause, but soon thereafter FSH and estradiol may return to the normal premenopausal range (",
"      <a class=\"graphic graphic_figure graphicRef82324 \" href=\"UTD.htm?23/42/24239\">",
"       figure 6",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations and endocrinology of the menopausal transition are reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link&amp;anchor=H171787387#H171787387\">",
"     \"Clinical manifestations and diagnosis of menopause\", section on 'Menstrual cycle and endocrine changes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the decline in follicular number, there may be a decrease in hypothalamic-pituitary sensitivity to estrogen during perimenopause. This was illustrated in a study of 160 perimenopausal women with anovulatory menstrual cycles who collected daily urine samples (across one cycle) for gonadotropin and sex steroid levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/51\">",
"     51",
"    </a>",
"    ]. Some cycles were characterized by normal preovulatory levels of estrogen, but no LH surge, suggesting a failure of estrogen-positive feedback, while in others, normal follicular phase estrogen levels did not suppress LH secretion, indicating a failure of estrogen-negative feedback.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179689159\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average age of menopause, defined as permanent cessation of menses, is age 51 years in normal women. [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/52\">",
"     52",
"    </a>",
"    ]. Clinical menopause is recognized after 12 months of amenorrhea. There is considerable variability around the onset of menopause with 5 percent of women undergoing menopause after age 55 and another 5 percent between ages 40 and 45 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Menopause before age 40 is considered abnormal, and is referred to as primary ovarian insufficiency (formerly called premature ovarian failure). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=see_link\">",
"     \"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179689166\">",
"    <span class=\"h3\">",
"     Factors affecting age at menopause",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors are thought to play a role in determining an individual woman's age of menopause, including genetics, ethnicity, smoking, and reproductive history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179689173\">",
"    <span class=\"h4\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a family history of early menopause are at higher risk for undergoing an earlier than average menopause themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/55\">",
"     55",
"    </a>",
"    ]. Additional evidence that genetic factors play are a role in the normal variation in age at natural menopause include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genome-wide association studies have identified regions associated with age at menopause [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. One meta-analysis points to genes regulating immune function and DNA repair [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genetic variation in the estrogen receptor gene may be another determinant of the age of menopause as illustrated in a study of 900 postmenopausal women in the Netherlands; the mean age at menopause varied by 1.1 year among women with different alleles at the same locus of the estrogen receptor gene [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The FMR1 premutation has been associated with premature ovarian failure and an earlier age of menopause by up to seven years [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=see_link\">",
"       \"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179689180\">",
"    <span class=\"h4\">",
"     Ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ethnicity and race may also affect the age of menopause. In two prospective, multiethnic, cohort studies, natural menopause occurred earlier among Hispanic women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/62\">",
"     62",
"    </a>",
"    ], and later in Japanese-American women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], when compared with Caucasian women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179689187\">",
"    <span class=\"h4\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age of menopause is reduced by about two years in women who smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/39,64-66\">",
"     39,64-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179689194\">",
"    <span class=\"h4\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors that may be associated with earlier menopause include galactose consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/53,67\">",
"     53,67",
"    </a>",
"    ], the presence of a variant form of galactose-1-phosphate uridyl transferase [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/53,68\">",
"     53,68",
"    </a>",
"    ], a history of type 1 diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/69\">",
"     69",
"    </a>",
"    ], and in utero exposure to diethylstilbestrol (DES) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179689201\">",
"    <span class=\"h4\">",
"     Hysterectomy with ovarian conservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy appears to alter ovarian function over the long-term, even if the ovaries are conserved. This effect is incompletely understood. Observational data have shown that women who undergo hysterectomy develop menopausal symptoms and menopausal hormone profiles earlier than controls who were not exposed to this surgery, possibly due to impairment of the ovarian blood supply or other yet unknown mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15706?source=see_link&amp;anchor=H12798793#H12798793\">",
"     \"Elective oophorectomy or ovarian conservation at the time of hysterectomy\", section on 'Early menopause following hysterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ultrasound findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer techniques of ovarian ultrasonography have revealed small (1 to 3 mm) cysts in the ovaries of women many years after the menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. These cysts probably represent secondary follicles, because a primordial follicle cannot begin to grow and mature unless it contains a viable oocyte, and follicles are the major cystic structures in the ovaries. It is not clear how long an intact oocyte must be present for follicular growth to occur and antral fluid to accumulate, and ultrasonography cannot detect follicular atresia. As a result, the importance of these small cysts in postmenopausal women is currently unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neuroendocrine changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging is associated with changes in hypothalamic-pituitary, as well as ovarian, function. The FSH and LH secreted by postmenopausal women contain more carbohydrate, and the serum half-lives of the hormones are prolonged as compared with young women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/71\">",
"     71",
"    </a>",
"    ]. The prolonged half-life contributes to the high serum FSH and LH concentrations found in older women. In addition, the FSH and LH secreted by older women may be less biologically active [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, some of the decline in ovarian function at the time of the menopause may be due to changes in the quantity or quality of the hormones secreted by the hypothalamus and pituitary or the pattern of their secretion, rather than to a primary loss of ovarian responsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/73\">",
"     73",
"    </a>",
"    ]. However, the poor response to exogenous administration of gonadotropins in older women undergoing in vitro fertilization argues against this possibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nomenclature",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nomenclature for the different phases of reproductive senescence has been confusing. In an attempt to define the stages of reproductive aging and its clinical and biochemical markers, the Stages of Reproductive Aging Workshop (STRAW) was held to develop a useful staging system and to revise the nomenclature (",
"    <a class=\"graphic graphic_figure graphicRef82933 \" href=\"UTD.htm?34/59/35760\">",
"     figure 4",
"    </a>",
"    ). This system provides useful clinical definitions of the menopausal transition, perimenopause, menopause, and postmenopause [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15720/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Follicular growth is initiated in the fetus in a continuous pattern that is independent of gonadotropins and is related to both the total mass of follicles and to factors released by atretic follicles. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ovarian development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cycles of follicular growth and subsequent atresia begin before birth and continue throughout the reproductive years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ovarian development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oocyte viability declines in older women of reproductive age before they have any measurable decrease in serum or intrafollicular hormone concentrations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Ovarian function during the reproductive years'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Menopause is associated with a marked decline in oocyte number that is attributable to progressive atresia of the original complement of oocytes. However, the evidence for absolute oocyte depletion at this time is limited. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Menopausal years'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The average age of menopause, defined as permanent cessation of menses, is age 51 years in normal women. Clinical menopause is recognized after 12 months of amenorrhea.",
"     </li>",
"     <li>",
"      A number of factors appear to be associated with age at menopause. (See",
"      <a class=\"local\" href=\"#H179689166\">",
"       'Factors affecting age at menopause'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Revised nomenclature, referred to as the STRAW staging system, is now typically used to describe the stages of the menopausal transition and postmenopause. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Nomenclature'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/1\">",
"      Huynh KD, Lee JT. Inheritance of a pre-inactivated paternal X chromosome in early mouse embryos. Nature 2003; 426:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/2\">",
"      Gartler SM, Liskay RM, Campbell BK, et al. Evidence for two functional X chromosomes in human oocytes. Cell Differ 1972; 1:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/3\">",
"      BAKER TG. A QUANTITATIVE AND CYTOLOGICAL STUDY OF GERM CELLS IN HUMAN OVARIES. Proc R Soc Lond B Biol Sci 1963; 158:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/4\">",
"      Jost A, Vigier B, Pr&eacute;pin J, Perchellet JP. Studies on sex differentiation in mammals. Recent Prog Horm Res 1973; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/5\">",
"      Gustafson ML, Lee MM, Scully RE, et al. M&uuml;llerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med 1992; 326:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/6\">",
"      Orsini LF, Salardi S, Pilu G, et al. Pelvic organs in premenarcheal girls: real-time ultrasonography. Radiology 1984; 153:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/7\">",
"      diZerega GS, Hodgen GD. Folliculogenesis in the primate ovarian cycle. Endocr Rev 1981; 2:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/8\">",
"      Peters H, Byskov AG, Himelstein-Braw R, Faber M. Follicular growth: the basic event in the mouse and human ovary. J Reprod Fertil 1975; 45:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/9\">",
"      Goldenberg RL, Powell RD, Rosen SW, et al. Ovarian morphology in women with anosmia and hypogonadotropic hypogonadism. Am J Obstet Gynecol 1976; 126:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/10\">",
"      Baker TG, Scrimgeour JB. Development of the gonad in normal and anencephalic human fetuses. J Reprod Fertil 1980; 60:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/11\">",
"      May JV, McCarty K Jr, Reichert LE Jr, Schomberg DW. Follicle-stimulating hormone-mediated induction of functional luteinizing hormone/human chorionic gonadotropin receptors during monolayer culture of porcine granulosa cells. Endocrinology 1980; 107:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/12\">",
"      Peters H, Byskov AG, Grinsted J. Follicular growth in fetal and prepubertal ovaries of humans and other primates. Clin Endocrinol Metab 1978; 7:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/13\">",
"      Lintern-Moore S, Peters H, Moore GP, Faber M. Follicular development in the infant human ovary. J Reprod Fertil 1974; 39:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/14\">",
"      Himelstein-Braw R, Byskov AG, Peters H, Faber M. Follicular atresia in the infant human ovary. J Reprod Fertil 1976; 46:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/15\">",
"      Apter D, Cacciatore B, Alfthan H, Stenman UH. Serum luteinizing hormone concentrations increase 100-fold in females from 7 years to adulthood, as measured by time-resolved immunofluorometric assay. J Clin Endocrinol Metab 1989; 68:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/16\">",
"      Jakacki RI, Kelch RP, Sauder SE, et al. Pulsatile secretion of luteinizing hormone in children. J Clin Endocrinol Metab 1982; 55:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/17\">",
"      Morita Y, Tilly JL. Oocyte apoptosis: like sand through an hourglass. Dev Biol 1999; 213:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/18\">",
"      Hirshfield AN. Effect of a low dose of pregnant mare's serum gonadotropin on follicular recruitment and atresia in cycling rats. Biol Reprod 1986; 35:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/19\">",
"      Richards JS. Molecular loci for potential drug toxicity in ovaries. Environ Health Perspect 1986; 70:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/20\">",
"      Tsafriri A, Channing CP. An inhibitory influence of granulosa cells and follicular fluid upon porcine oocyte meiosis in vitro. Endocrinology 1975; 96:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/21\">",
"      Hillensj&ouml; T, Batta SK, Schwartz-Kripner A, et al. Inhibitory effect of human follicular fluid upon the maturation of porcine oocytes in culture. J Clin Endocrinol Metab 1978; 47:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/22\">",
"      Ueno S, Manganaro TF, Donahoe PK. Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro. Endocrinology 1988; 123:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/23\">",
"      Tsafriri A, Picard JY, Josso N. Immunopurified anti-m&uuml;llerian hormone does not inhibit spontaneous resumption of meiosis in vitro of rat oocytes. Biol Reprod 1988; 38:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/24\">",
"      Ueno S, Kuroda T, Maclaughlin DT, et al. Mullerian inhibiting substance in the adult rat ovary during various stages of the estrous cycle. Endocrinology 1989; 125:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/25\">",
"      Perez GI, Robles R, Knudson CM, et al. Prolongation of ovarian lifespan into advanced chronological age by Bax-deficiency. Nat Genet 1999; 21:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/26\">",
"      Ratts VS, Flaws JA, Kolp R, et al. Ablation of bcl-2 gene expression decreases the numbers of oocytes and primordial follicles established in the post-natal female mouse gonad. Endocrinology 1995; 136:3665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/27\">",
"      Vaskivuo TE, Anttonen M, Herva R, et al. Survival of human ovarian follicles from fetal to adult life: apoptosis, apoptosis-related proteins, and transcription factor GATA-4. J Clin Endocrinol Metab 2001; 86:3421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/28\">",
"      Johnson J, Canning J, Kaneko T, et al. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 2004; 428:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/29\">",
"      Johnson J, Bagley J, Skaznik-Wikiel M, et al. Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood. Cell 2005; 122:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/30\">",
"      Eggan K, Jurga S, Gosden R, et al. Ovulated oocytes in adult mice derive from non-circulating germ cells. Nature 2006; 441:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/31\">",
"      Zou K, Yuan Z, Yang Z, et al. Production of offspring from a germline stem cell line derived from neonatal ovaries. Nat Cell Biol 2009; 11:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/32\">",
"      BLOCK E. Quantitative morphological investigations of the follicular system in women; variations at different ages. Acta Anat (Basel) 1952; 14:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/33\">",
"      Baker TG. Radiosensitivity of mammalian oocytes with particular reference to the human female. Am J Obstet Gynecol 1971; 110:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/34\">",
"      Costoff A, Mahesh VB. Primordial follicles with normal oocytes in the ovaries of postmenopausal women. J Am Geriatr Soc 1975; 23:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/35\">",
"      Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 1987; 65:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/36\">",
"      Klein NA, Battaglia DE, Miller PB, et al. Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age. J Clin Endocrinol Metab 1996; 81:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/37\">",
"      Maroulis, GB. Effect of aging on fertility and pregnancy. Semin Reprod Endocrinol 1991; 9:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/38\">",
"      Santoro N, Schneyer AL, Ibrahim J, Schmidt CL. Gonadotropin and inhibin concentrations in early pregnancy in women with and without corpora lutea. Obstet Gynecol 1992; 79:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/39\">",
"      McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Ann Intern Med 1985; 103:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/40\">",
"      Freeman EW, Sammel MD, Gracia CR, et al. Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. Fertil Steril 2005; 83:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/41\">",
"      Burger HG, Cahir N, Robertson DM, et al. Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. Clin Endocrinol (Oxf) 1998; 48:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/42\">",
"      Welt CK, McNicholl DJ, Taylor AE, Hall JE. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 1999; 84:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/43\">",
"      van Rooij IA, Broekmans FJ, Scheffer GJ, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005; 83:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/44\">",
"      M&eacute;duri G, Massin N, Guibourdenche J, et al. Serum anti-M&uuml;llerian hormone expression in women with premature ovarian failure. Hum Reprod 2007; 22:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/45\">",
"      van Disseldorp J, Faddy MJ, Themmen AP, et al. Relationship of serum antim&uuml;llerian hormone concentration to age at menopause. J Clin Endocrinol Metab 2008; 93:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/46\">",
"      La Marca A, Giulini S, Tirelli A, et al. Anti-M&uuml;llerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007; 22:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/47\">",
"      Sowers MR, Eyvazzadeh AD, McConnell D, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008; 93:3478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/48\">",
"      Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996; 81:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/49\">",
"      Taffe JR, Dennerstein L. Menstrual patterns leading to the final menstrual period. Menopause 2002; 9:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/50\">",
"      Hee J, MacNaughton J, Bangah M, Burger HG. Perimenopausal patterns of gonadotrophins, immunoreactive inhibin, oestradiol and progesterone. Maturitas 1993; 18:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/51\">",
"      Weiss G, Skurnick JH, Goldsmith LT, et al. Menopause and hypothalamic-pituitary sensitivity to estrogen. JAMA 2004; 292:2991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/52\">",
"      McKinlay SM. The normal menopause transition: an overview. Maturitas 1996; 23:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/53\">",
"      Cramer DW, Barbieri RL, Xu H, Reichardt JK. Determinants of basal follicle-stimulating hormone levels in premenopausal women. J Clin Endocrinol Metab 1994; 79:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/54\">",
"      McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992; 14:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/55\">",
"      de Bruin JP, Bovenhuis H, van Noord PA, et al. The role of genetic factors in age at natural menopause. Hum Reprod 2001; 16:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/56\">",
"      He, C, Kraft, P, Chen, C, et al. Nat Genet 2009; 41:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/57\">",
"      Stolk, L, Zhai, G, van Meurs, JBJ, et al. Nat Genet 2009; 41:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/58\">",
"      Stolk L, Perry JR, Chasman DI, et al. Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet 2012; 44:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/59\">",
"      Weel AE, Uitterlinden AG, Westendorp IC, et al. Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab 1999; 84:3146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/60\">",
"      Sullivan AK, Marcus M, Epstein MP, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod 2005; 20:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/61\">",
"      Allen EG, Sullivan AK, Marcus M, et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod 2007; 22:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/62\">",
"      Henderson KD, Bernstein L, Henderson B, et al. Predictors of the timing of natural menopause in the Multiethnic Cohort Study. Am J Epidemiol 2008; 167:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/63\">",
"      Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001; 153:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/64\">",
"      Kaufman DW, Slone D, Rosenberg L, et al. Cigarette smoking and age at natural menopause. Am J Public Health 1980; 70:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/65\">",
"      Willett W, Stampfer MJ, Bain C, et al. Cigarette smoking, relative weight, and menopause. Am J Epidemiol 1983; 117:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/66\">",
"      Cramer DW, Barbieri RL, Fraer AR, Harlow BL. Determinants of early follicular phase gonadotrophin and estradiol concentrations in women of late reproductive age. Hum Reprod 2002; 17:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/67\">",
"      Cooper GS, Hulka BS, Baird DD, et al. Galactose consumption, metabolism, and follicle-stimulating hormone concentrations in women of late reproductive age. Fertil Steril 1994; 62:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/68\">",
"      Cramer DW, Harlow BL, Barbieri RL, Ng WG. Galactose-1-phosphate uridyl transferase activity associated with age at menopause and reproductive history. Fertil Steril 1989; 51:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/69\">",
"      Dorman JS, Steenkiste AR, Foley TP, et al. Menopause in type 1 diabetic women: is it premature? Diabetes 2001; 50:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/70\">",
"      Hatch EE, Troisi R, Wise LA, et al. Age at natural menopause in women exposed to diethylstilbestrol in utero. Am J Epidemiol 2006; 164:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/71\">",
"      Wide L, Hobson BM. Qualitative difference in follicle-stimulating hormone activity in the pituitaries of young women compared to that of men and elderly women. J Clin Endocrinol Metab 1983; 56:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/72\">",
"      Chappel SC, Ulloa-Aguirre A, Coutifaris C. Biosynthesis and secretion of follicle-stimulating hormone. Endocr Rev 1983; 4:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/73\">",
"      Wise PM, Krajnak KM, Kashon ML. Menopause: the aging of multiple pacemakers. Science 1996; 273:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15720/abstract/74\">",
"      Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001; 76:874.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7434 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15720=[""].join("\n");
var outline_f15_22_15720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVARIAN DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Germ cell differentiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Continuous follicular growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Continuous follicular atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OVARIAN FUNCTION DURING THE REPRODUCTIVE YEARS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MENOPAUSAL YEARS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Menopausal transition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179689159\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H179689166\">",
"      - Factors affecting age at menopause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H179689173\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H179689180\">",
"      Ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H179689187\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H179689194\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H179689201\">",
"      Hysterectomy with ovarian conservation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ultrasound findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neuroendocrine changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nomenclature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7434\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7434|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/43/16062\" title=\"figure 1\">",
"      Follicle number and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/58/19375\" title=\"figure 2\">",
"      Fertility rate and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/53/31583\" title=\"figure 3\">",
"      Hormone levels reproductive age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/59/35760\" title=\"figure 4\">",
"      STRAW staging system for reproductive aging women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/16/36111\" title=\"figure 5\">",
"      Early transition hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/42/24239\" title=\"figure 6\">",
"      Onset menopausal transition",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=related_link\">",
"      Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15706?source=related_link\">",
"      Elective oophorectomy or ovarian conservation at the time of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=related_link\">",
"      Normal sexual differentiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=related_link\">",
"      Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_22_15721="Cold urticaria";
var content_f15_22_15721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cold urticaria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/22/15721/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15721/contributors\">",
"     Marcus Maurer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/22/15721/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15721/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15721/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/22/15721/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15721/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/22/15721/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold urticaria, or cold contact urticaria, is a subtype of physical urticaria (",
"    <a class=\"graphic graphic_table graphicRef50072 \" href=\"UTD.htm?33/35/34364\">",
"     table 1",
"    </a>",
"    ). It is characterized by pruritic wheals (hives or urticaria)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema due to cutaneous mast cell activation and release of proinflammatory mediators after cold exposure. Triggers include cold objects, cold liquids, and cold air. The underlying pathophysiology is largely unknown.",
"   </p>",
"   <p>",
"    Cold urticaria is reviewed here. Other urticaria disorders, including acute and chronic spontaneous urticaria and other forms of physical urticaria, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=see_link\">",
"     \"Physical urticarias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link\">",
"     \"Chronic urticaria: Standard management and patient education\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of cold urticaria was estimated to be 0.05 percent in Central Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/1\">",
"     1",
"    </a>",
"    ]. The frequency of cold urticaria among physical urticaria subtypes varies between 5 and 34 percent, partly depending upon the geographic region (ie, higher incidences are found in regions with colder climates and lower rates are seen in regions with a warmer climate) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cold urticaria most frequently affects young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Both sexes are affected with similar frequency in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/1,3,6\">",
"     1,3,6",
"    </a>",
"    ], although one study reported that females were affected twice as often as males [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/5\">",
"     5",
"    </a>",
"    ]. Up to half of patients with cold urticaria are atopic and one-fourth have other types of inducible urticaria, most commonly symptomatic dermographism and cholinergic urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold urticaria symptoms result from the activation of mast cells and subsequent release of histamine and other proinflammatory mediators. Following a cold stimulation test, cutaneous mast cells in patients with cold urticaria show signs of degranulation, and serum levels of mast cell mediators are increased [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. This results in pruritus, burning and erythema from activation of skin nerves, and vasodilation of skin vessels with extravasation causing wheals and angioedema.",
"   </p>",
"   <p>",
"    A variety of laboratory abnormalities have been found in patients with cold urticaria, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small series, the majority of patients with cold urticaria exhibited mast cell-activating anti-IgE antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Associations noted in case reports include cryoglobulinemia, anti-lamin-B antibodies, reduced levels of C1-esterase inhibitor and C4, and increased levels of platelet-activating factor and platelet factor 4 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/12-16\">",
"       12-16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4450715\">",
"    <span class=\"h2\">",
"     Associated disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of diseases have been associated with essential cold urticaria, largely in case reports. The causal relationship between these various disorders and cold urticaria is unknown. Associations have been reported with viral, parasitic, and bacterial infections, including Lyme disease, hepatitis, infectious mononucleosis, acute toxoplasmosis, Helicobacter pylori colonization, and HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. In addition, cold urticaria has been associated with antecedent Hymenoptera stings, food and drug intolerance, and hematologic, lymphatic, or neoplastic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of the most common form of cold urticaria consist of cutaneous urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema. A subset of patients develops systemic reactions. Variant forms have specific characteristic features that can be elicited by a careful clinical history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23479940\">",
"    <span class=\"h2\">",
"     Cutaneous signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold urticaria is characterized by the development of wheal-and-flare skin reactions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema after the skin is exposed to cold air, liquids, or objects (",
"    <a class=\"graphic graphic_picture graphicRef50151 \" href=\"UTD.htm?20/36/21058\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/24\">",
"     24",
"    </a>",
"    ]. Wheals and angioedema typically develop minutes after exposure. Cold urticaria symptoms are usually limited to cold-exposed skin areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23479947\">",
"    <span class=\"h2\">",
"     Systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive cold contact may result in systemic reactions, ranging from generalized urticaria to anaphylaxis, with symptoms involving the respiratory, gastrointestinal,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiovascular systems [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/6\">",
"     6",
"    </a>",
"    ]. In a series of 30 children with cold urticaria seen in a tertiary referral center, one-third had a history of cold-induced anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/7\">",
"     7",
"    </a>",
"    ]. In another series of mostly adult patients, also from a tertiary referral clinic, nearly one-third experienced at least one severe systemic reaction with hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory compromise, and approximately half of patients reported milder cutaneous systemic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/3\">",
"     3",
"    </a>",
"    ]. In these two studies, almost all patients reported reactions triggered by aquatic activities, whereas only 30 percent experienced symptoms after touching a cold object.",
"   </p>",
"   <p>",
"    Patients with cold urticaria who participate in aquatic activities (eg, swimming in cold water) are at risk of death both directly from anaphylaxis and indirectly from drowning during a reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/5,6,25\">",
"     5,6,25",
"    </a>",
"    ]. Patients with cold urticaria are also at risk of suffocation due to oropharyngeal angioedema after consuming cold foods or beverages, although it is unclear how commonly this occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4451196\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some risk factors or predictors of systemic reactions have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the pediatric study described above, the only risk factor identified was a history of a previous cold-induced systemic reaction [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, patients with a history of cold-induced oropharyngeal angioedema were at greater risk of a systemic reaction triggered by swimming, compared to those with a history of only a few hives after swimming [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe systemic reactions may be more frequent in patients &lt;30 years old at disease onset [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical variables associated with systemic reactions include a greater surface area of skin exposed, exposure to lower temperatures, and longer duration of cold exposure. Exposure to cold water or solid objects that are cold is more likely to elicit symptoms than exposure to cold air. We also advise patients to pay attention to the wind chill factor during cold months, as symptoms will be more easily triggered on days when the wind chill is significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3768741\">",
"    <span class=\"h2\">",
"     Variant forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several variant forms of cold urticaria (atypical cold urticarias). In all of these disorders, the standard cold stimulation test is negative. Each involves urticarial lesions, although the specific triggers, timing, or location of the lesions is different from classic cold urticaria. Some are acquired and others are hereditary [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/10,26\">",
"     10,26",
"    </a>",
"    ]. Modified types of cold stimulation testing are needed to elicit the signs and symptoms. (See",
"    <a class=\"local\" href=\"#H23480286\">",
"     'Cold stimulation tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In delayed cold urticaria, which has both acquired and hereditary forms, the wheal-and-flare reaction occurs up to 24 hours after cold exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. This is a rare disorder. Hyperpigmentation typically develops at the site of lesions as they resolve in the familial form. Patients with this disorder will have no immediate response to CST, but will develop a wheal-and-flare response at the test site 18 to 24 hours later.",
"     </li>",
"     <li>",
"      In familial atypical cold urticaria, symptoms are lifelong and begin in early childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/29\">",
"       29",
"      </a>",
"      ]. Localized urticaria typically develops on areas exposed to cold air, water, or objects. Symptoms triggered by cold food and beverages are also common. Systemic inflammatory symptoms are absent. CST was negative in the small number of patients described.",
"     </li>",
"     <li>",
"      In a recently described syndrome of familial cold urticaria related to deletions in the gene for phospholipase C&gamma;2, affected individuals also have cold urticaria from childhood, although symptoms are elicited by evaporative cooling (eg, exposure to cold air or wind), rather than touching cold objects or water, and autoimmunity and immunodeficiency are each present in about one-half of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/30\">",
"       30",
"      </a>",
"      ]. Investigators suggested the condition be called",
"      <em>",
"       PLC&gamma;2",
"      </em>",
"      -associated antibody deficiency and immune dysregulation, or PLAID.",
"     </li>",
"     <li>",
"      In patients with cold-dependent dermographism, the skin becomes dermographic when cooled [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. To reproduce this, the skin should be stroked firmly while cool, and then rewarmed.",
"     </li>",
"     <li>",
"      In cold-induced cholinergic urticaria, generalized hives only develop when exercising in cold environments [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/33\">",
"       33",
"      </a>",
"      ]. The diagnosis is often made by clinical history alone, and would be confirmed by exercise challenge in a cold room.",
"     </li>",
"     <li>",
"      In systemic cold urticaria, generalized urticaria is seen after systemic cold exposure. This form is not associated with exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/34\">",
"       34",
"      </a>",
"      ]. CST is negative and the diagnosis is usually based upon clinical history and confirmed by cold exposure in a cold room.",
"     </li>",
"     <li>",
"      In localized cold urticaria, hives only develop at defined skin sites, such as the face [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. Thus, the CST is only positive if performed at these sites.",
"     </li>",
"     <li>",
"      In localized cold reflex urticaria, hives develop near (within a few centimeters), but not directly where, the ice cube was applied [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with a suggestive clinical history, the diagnosis of cold urticaria is confirmed by a positive reaction to a cold stimulation test [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/10,39,40\">",
"     10,39,40",
"    </a>",
"    ]. As mentioned previously, modified types of tests are often needed for variant forms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23480286\">",
"    <span class=\"h2\">",
"     Cold stimulation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cold stimulation test (CST) can be performed by several different methods. All methods involve the application of a cold object to the skin and then removing the stimulus and allowing the skin to rewarm. The test is considered positive if the test site shows a palpable and clearly visible wheal-and-flare skin reaction upon rewarming. The affected site is pruritic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    associated with a burning sensation in most cases. The test is considered negative if there is no reaction, or erythema or",
"    <span class=\"nowrap\">",
"     pruritus/burning",
"    </span>",
"    only.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23480071\">",
"    <span class=\"h3\">",
"     Ice cube test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ice cube test, which requires no special equipment, involves placing an ice cube in a thin plastic bag and waiting for melting to begin (to avoid cold damage to the skin), then placing the bag against the skin (usually of the volar forearm) for five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/25\">",
"     25",
"    </a>",
"    ]. Response is assessed 10 minutes after removal (",
"    <a class=\"graphic graphic_picture graphicRef55636 \" href=\"UTD.htm?26/31/27123\">",
"     picture 2",
"    </a>",
"    ). This method is readily performed in most offices and has a sensitivity of 83 to 90 percent and a specificity of 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/5,39\">",
"     5,39",
"    </a>",
"    ]. Longer periods of exposure are rarely needed.",
"   </p>",
"   <p>",
"    If no wheal has developed, we revisit the history to see if a variant form may be present. As an example, we might ask the patient again if there are only certain areas of the body on which cold-induced wheals",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema have formed in the past (suggesting localized cold urticaria). Modified testing can sometimes elicit a positive test, as described previously (See",
"    <a class=\"local\" href=\"#H3768741\">",
"     'Variant forms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4448940\">",
"    <span class=\"h3\">",
"     Specialized testing devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;TempTest",
"    <sup>",
"     &reg;",
"    </sup>",
"    3.0 (EMO Systems GmbH, Berlin, Germany) is a thermoelectric device that performs cold stimulation tests at multiple different temperatures simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/39\">",
"     39",
"    </a>",
"    ]. Its sensitivity and specificity (93 and 100 percent, respectively) are similar to the ice cube test. The TempTest",
"    <sup>",
"     &reg;",
"    </sup>",
"    can be used to confirm the diagnosis of cold urticaria, as well as determine a patient&rsquo;s thresholds. (See",
"    <a class=\"local\" href=\"#H23480278\">",
"     'Threshold testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23480244\">",
"    <span class=\"h3\">",
"     Cold packs and cold water baths",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold provocation testing using cold packs or cold water baths is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for first-line screening, because these methods expose larger areas of skin to cold and may induce systemic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. Rather, they are usually used to evaluate patients in whom the ice cube or TempTest",
"    <sup>",
"     &reg;",
"    </sup>",
"    method was negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1727555\">",
"    <span class=\"h3\">",
"     Natural exposure testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some situations, the most logical way to diagnose a cold-induced disorder is to ask the patient to reexpose themselves to the conditions (eg, cold wind, cold water) that elicited the signs and symptoms in the first place, if safe and feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1485884\">",
"    <span class=\"h2\">",
"     Laboratory tests to exclude other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A laboratory evaluation is not needed in routine cases of cold-induced urticaria in children or adults. Underlying causes can only be identified in a minority of patients with cold urticaria, even if comprehensive testing is performed. If the patient&rsquo;s symptoms are not typical for cold-induced urticaria or suggest the presence of systemic disease or an associated condition, then appropriate studies are indicated. (See",
"    <a class=\"local\" href=\"#H4450715\">",
"     'Associated disorders'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23480278\">",
"    <span class=\"h2\">",
"     Threshold testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author's approach in patients who show a positive initial test reaction is to further define the temperature and time thresholds for the individual patient using the TempTest",
"    <sup>",
"     &reg;",
"    </sup>",
"    device. Threshold testing is not necessary for the diagnosis, although the information (especially the temperature threshold) can help patients avoid risky situations. It also allows clinicians to assess the likelihood that a patient will be able to avoid situations that trigger symptoms and can be used to monitor treatment responses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. There are two threshold determinations that are relevant to patient care [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The critical temperature threshold, which is the highest temperature sufficient to induce a positive test reaction (",
"      <a class=\"graphic graphic_picture graphicRef80086 \" href=\"UTD.htm?19/4/19522\">",
"       picture 3",
"      </a>",
"      ), and",
"     </li>",
"     <li>",
"      The cold stimulation time threshold, or the shortest duration of cold exposure required to induce a positive test reaction (",
"      <a class=\"graphic graphic_picture graphicRef69400 \" href=\"UTD.htm?5/37/5713\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study of 45 patients with cold urticaria found a mean (+ SEM) critical temperature threshold of 17 (+ 6) degrees Celsius or approximately 63 (+ 11) degrees Fahrenheit (range 4 to 27 degrees Celsius or approximately 39 to 81 degrees Fahrenheit) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, patients&rsquo; thresholds may vary significantly. Patients with higher threshold temperatures are considered to have more severe disease, although disease severity does not appear to predict response to antihistamine therapy, as discussed below. (See",
"    <a class=\"local\" href=\"#H4449650\">",
"     'Dose'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One important caveat about threshold determinations is the following: There are no data indicating that threshold levels are the same whether the area of exposure is localized, such as exposure of the face to a cold wind, versus a large area, such as submersion in cold water. We advise patients that if they are faced with a situation in which symptoms might occur (such as swimming in a pool), they can expose a limited area of the body first (eg, submerge a hand) and then wait to see if symptoms appear before exposing the rest of the body.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other disorders in which symptoms are induced by cold exposure include familial cold autoinflammatory syndrome and disorders caused by cold-induced abnormal serum proteins. CST would be negative if performed in patients with these disorders. Patients do not develop typical urticaria, distinguishing these disorders from typical or variant forms of cold urticaria.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with familial cold autoinflammatory syndrome (FCAS) present within the first few months of life. The development of a papular rash after cold exposure is often delayed by up to several hours. This form is associated with systemic inflammatory symptoms, including fever, conjunctival injection, and arthralgias. The presence of systemic symptoms distinguishes this disorder from simple cold urticaria. FCAS is considered a hereditary periodic fever syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=see_link&amp;anchor=H5#H5\">",
"       \"Cryopyrin-associated periodic syndromes and related disorders\", section on 'Familial cold autoinflammatory syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Several other diseases involve abnormal cold-dependent immunoglobulins, including cryoglobulinemia, cryofibrinogenemia, cold agglutinin disease, and paroxysmal cold hemoglobinuria. Patients with these disorders do not present with cold urticaria, but rather with signs and symptoms of cutaneous (ie, purpura) or systemic vasculitis, renal disease, or other organ system manifestations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=see_link\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7576?source=see_link\">",
"       \"Cryofibrinogenemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33672?source=see_link\">",
"       \"Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=see_link\">",
"       \"Paroxysmal cold hemoglobinuria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10165653\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Straightforward cases of cold urticaria may be diagnosed and managed by generalists. We suggest referral to an",
"    <span class=\"nowrap\">",
"     allergy/immunology",
"    </span>",
"    expert if the clinician is not comfortable performing diagnostic testing, and in cases involving systemic symptoms or atypical symptoms, or if symptoms prove difficult to manage. Patients with cold-induced symptoms that are suggestive of an autoinflammatory or vasculitis disorder should be referred to a specialist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of cold urticaria consists of the following elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Education about the risks of systemic reactions",
"     </li>",
"     <li>",
"      Preparation for treatment of acute symptoms",
"     </li>",
"     <li>",
"      Practical advice to avoid cold exposure",
"     </li>",
"     <li>",
"      Antihistamine therapy for prophylaxis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other adjunctive therapies may also be helpful. Successful desensitization protocols have been described, but this approach requires daily cold exposure to maintain the desensitized state and is impractical for most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4449202\">",
"    <span class=\"h2\">",
"     Education about high-risk activities and cold avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cold urticaria should be counseled that certain activities and procedures may trigger systemic reactions or serious localized reactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Swimming is the activity that most commonly induces systemic symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/3,7\">",
"       3,7",
"      </a>",
"      ]. Patients who chose to continue to participate in aquatic activities should avoid subthreshold temperature exposures, if a threshold is known for that patient. A water temperature above 77 degrees Fahrenheit (25 degrees Celsius) is sufficient for most patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/7\">",
"       7",
"      </a>",
"      ]. Wetsuits may be helpful, although this has not been formally studied.",
"     </li>",
"     <li>",
"      Consumption of cold foods or beverages can induce oropharyngeal angioedema or anaphylaxis.",
"     </li>",
"     <li>",
"      Surgery is another setting in which patients with cold urticaria can develop systemic reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. The surgery and anesthesia teams should be informed about the patient&rsquo;s condition and should make efforts to keep the patient sufficiently warm throughout the procedure. Treatment for any symptoms that may develop should be immediately available. Premedication with antihistamines could be considered in patients with past systemic reactions to cold exposure.",
"     </li>",
"     <li>",
"      Administration of cold intravenous solutions or injections can induce symptoms in some patients. Intravenous fluids or injected medications should be prewarmed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General cold avoidance is recommended, since it is the most logical way to prevent symptoms. However, avoidance is not always possible. Knowledge of their temperature threshold can help patients to recognize and avoid critical cold exposure in their daily lives [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pretreatment with an antihistamine prior to predictable cold exposure is recommended, because clinical experience suggests that antihistamine pretreatment prevents skin reactions and systemic reactions. In addition, patients of all ages at increased risk of systemic reactions should have an epinephrine autoinjector readily available and should be accompanied by an adult who is trained in its use. (See",
"    <a class=\"local\" href=\"#H1486254\">",
"     'Epinephrine for systemic symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3768893\">",
"    <span class=\"h2\">",
"     Treatment of acute signs and symptoms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1486254\">",
"    <span class=\"h3\">",
"     Epinephrine for systemic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epinephrine is effective treatment for anaphylaxis caused by other triggers, and it appears to be effective in this setting as well, based upon clinical experience and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. We recommend that patients with cold urticaria who have a history of anaphylaxis, systemic symptoms, frequent and unavoidable cold exposure,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a high temperature threshold be prescribed and carry an epinephrine autoinjector and be taught how and when to use this device. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=see_link\">",
"     \"Prescribing epinephrine for anaphylaxis self-treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9401?source=see_link\">",
"     \"Anaphylaxis: Confirming the diagnosis and determining the trigger(s)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"     \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3768986\">",
"    <span class=\"h3\">",
"     Treatment of milder symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author also suggests patients carry a few doses of H1 antihistamine, for use in treating systemic symptoms that do not require therapy with epinephrine (eg, extensive urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema not involving the airway). Patients with significant angioedema may benefit from a short course of oral glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3768840\">",
"    <span class=\"h2\">",
"     Preventative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;H1 antihistamines are the primary prophylactic therapy for cold urticaria and have proven efficacy in small randomized trials. Other therapies have been reported to be helpful in series of a few patients each.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1487514\">",
"    <span class=\"h3\">",
"     H1 antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;H1 antihistamines have been shown in randomized trials to reduce the frequency and severity of",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    episodes, as with other forms of chronic urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link&amp;anchor=H9#H9\">",
"     \"Chronic urticaria: Standard management and patient education\", section on 'H1 antihistamines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonsedating second-generation H1 antihistamines are preferred for chronic treatment, although some of these medications may be sedating at higher doses. Several H1 antihistamines have demonstrated efficacy in patients with cold urticaria (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12934?source=see_link\">",
"     desloratadine",
"    </a>",
"    , ebastine, and rupatadine; the last two are not available in the United States), whereas others have not been studied (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/45/44757?source=see_link\">",
"     levocetirizine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/48-51\">",
"     48-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     Cyproheptadine",
"    </a>",
"    was commonly used in the past for treatment of cold urticaria. However, this drug is not known to be superior to other antihistamines for the treatment of cold urticaria, and it has the well-known adverse effects of the older, first-generation antihistamines (eg, sedation, anticholinergic effects) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4449650\">",
"    <span class=\"h4\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;A higher than usual dose of antihistamine (eg, up to four times the daily recommended dose) is required for sufficient protection from urticarial symptoms in many patients with cold urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/49,50,52,54\">",
"     49,50,52,54",
"    </a>",
"    ]. Patients with cold urticaria who are incompletely treated with usual doses may suffer from severe and avoidable impairment in their quality of life. In addition, insufficiently treated patients with severe cold urticaria may be at greater risk of developing life-threatening reactions upon cold exposure, although the utility of antihistamines in preventing cold-induced systemic reactions have not been studied.",
"   </p>",
"   <p>",
"    The need for higher than standard doses was demonstrated in a randomized, three-way crossover trial of 30 patients with cold urticaria who were treated with 5 or 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12934?source=see_link\">",
"     desloratadine",
"    </a>",
"    or placebo daily (each for 7 days separated by 14-day washout periods) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/49\">",
"     49",
"    </a>",
"    ]. Response to therapy was assessed by cold stimulation testing using TempTest",
"    <sup>",
"     &reg;",
"    </sup>",
"    . Both antihistamine doses decreased wheal size 15 and 90 minutes after cold provocation testing, raised the critical temperature threshold, and increased the critical stimulation time compared with placebo. The 20 mg dose was significantly more effective than the 5 mg dose for each of the endpoints.",
"   </p>",
"   <p>",
"    Even with higher antihistamine doses, responses are variable and difficult to predict. This was shown in a subsequent randomized study of 30 patients, in which one-half received 5 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12934?source=see_link\">",
"     desloratadine",
"    </a>",
"    daily for six weeks, while the other one-half had the dose of desloratadine increased every two weeks to a maximum of 20 mg daily if symptoms were not controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/52\">",
"     52",
"    </a>",
"    ]. The severity of disease (ie, the higher the eliciting temperature, the more severe the disease) was assessed at baseline and monitored throughout by cold stimulation testing using TempTest",
"    <sup>",
"     &reg;",
"    </sup>",
"    3.0. No patient became symptom free on 5 mg desloratadine, while two became symptom free on 10 mg and a further three, on 20 mg desloratadine daily. About 20 percent of patients did not experience any significant improvement, and there was no correlation between initial severity and response to therapy.",
"   </p>",
"   <p>",
"    The author starts with the standard daily dose of a nonsedating second-generation antihistamine and increases it up to four times that dose if the patient continues to experience symptoms. In patients who have already tried standard doses of antihistamines without adequate relief, we sometimes start therapy with three times the usual dose and adjust higher or lower depending upon response.",
"   </p>",
"   <p>",
"    For patients who have been completely protected from cold-induced symptoms for at least six weeks on a higher than standard dose, the dose is then decreased over several months to the lowest level that provides complete protection. Patients are continued on a prophylactic antihistamine until they go into remission. The author typically discontinues the medication after three to six months to determine if remission has been achieved. Patients who participate in aquatic activities in the summer usually require year-round treatment, whereas other may need protection only during the winter months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other therapies have been administered to patients with severe cold urticaria and a high risk of life-threatening reactions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an insufficient response to antihistamines, as noted in case reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H2 antihistamines (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      150 mg twice daily), added to H1 antihistamines have been reported to be helpful in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/55\">",
"       55",
"      </a>",
"      ]. However, other patients experience no apparent benefit, and more conclusive studies are lacking.",
"     </li>",
"     <li>",
"      The addition of the leukotriene antagonists",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      appeared to be beneficial in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/56,57\">",
"       56,57",
"      </a>",
"      ], although not in others [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IgE therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      ), at the doses used for asthma, was effective in small numbers of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      (3 mg per kg daily) with subsequent dose reduction after the first month of treatment was successful in controlling symptoms in a patient refractory to high-dose antihistamines and glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/61\">",
"       61",
"      </a>",
"      ]. The use of cyclosporin in chronic urticaria, including dosing and monitoring, is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30554?source=see_link&amp;anchor=H13#H13\">",
"       \"Chronic urticaria: Treatment of refractory symptoms\", section on 'Cyclosporine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      , derived from chili peppers, prevented cold urticaria symptoms for four to seven days in a small case series [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/62\">",
"       62",
"      </a>",
"      ]. Capsaicin treatment results in the depletion of neuropeptides from sensory nerve fibers that may contribute to the induction of cold urticaria skin reactions. However, it causes local irritation at the site of application.",
"     </li>",
"     <li>",
"      Antibiotic therapy was reported to be effective for some patients with cold urticaria in two observational studies [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/1,63\">",
"       1,63",
"      </a>",
"      ]. In one of these series, 46 percent (13 of 28) of patients treated with high-dose oral penicillin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      for two to four weeks went into remission and an additional 29 percent noted attenuated symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/1\">",
"       1",
"      </a>",
"      ]. However, the rationale for its effectiveness is unclear, since this approach appeared to induce remission or decrease symptoms even when no underlying infection could be detected. Randomized controlled trials are needed to assess the efficacy of this treatment.",
"     </li>",
"     <li>",
"      Response to systemic glucocorticoids is variable [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/61,64\">",
"       61,64",
"      </a>",
"      ]. Those who respond usually do so only temporarily [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/65\">",
"       65",
"      </a>",
"      ]. Thus, glucocorticoids are not recommended for routine treatment of cold urticaria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The author&rsquo;s approach to treating cold urticaria that is refractory to H1 antihistamines is to add an H2 antihistamine (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    ) and a leukotriene antagonist (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    ). For patients who fail to respond to this treatment,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    may be helpful. However, omalizumab is only approved in the United States for the treatment of asthma. Reimbursement for this costly therapy by third-party payers for use in cold urticaria must be arranged on a patient-by-patient basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cold desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case series suggest that desensitization to cold (cold \"tolerance\" induction or hardening) by full-body",
"    <span class=\"nowrap\">",
"     baths/showers",
"    </span>",
"    in cold water can protect patients with cold urticaria from cold-induced symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. Patients are desensitized to the cold by repeatedly exposing increasingly larger skin areas to incrementally colder water, starting with above-threshold temperatures. This therapy decreases the critical temperature threshold.",
"   </p>",
"   <p>",
"    Cold-tolerance induction needs to be initiated with great caution and under a clinician's supervision because of the risk of severe systemic reactions. While the term \"tolerance\" is used, \"desensitization\" is more appropriate, since discontinuation for as little as a few days results in a complete loss of protection. Patients need to be informed that daily cold",
"    <span class=\"nowrap\">",
"     showers/baths",
"    </span>",
"    are required to maintain the desensitized state. Most patients do not continue this therapy for more than a few weeks to months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remission, or at least improvement of symptoms, occurs in 50 percent of patients within five to six years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/1,3,5,24\">",
"     1,3,5,24",
"    </a>",
"    ]. The mean time to resolution in one study was 5.6 &plusmn; 3.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15721/abstract/3\">",
"     3",
"    </a>",
"    ]. Recurrence of cold urticaria after remission is rare. Other patients have the disorder for many years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/27/44466?source=see_link\">",
"       \"Patient information: Physical hives (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cold urticaria is a subtype of physical urticaria characterized by itchy wheals",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioedema due to skin mast cell activation and the release of proinflammatory mediators after cold exposure (",
"      <a class=\"graphic graphic_picture graphicRef50151 \" href=\"UTD.htm?20/36/21058\">",
"       picture 1",
"      </a>",
"      ). The underlying causes are largely unknown. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cold urticaria symptoms are usually limited to cold-exposed skin areas and develop within minutes of cold exposure. However, extensive cold contact may result in systemic reactions. Occurrence of severe anaphylactic reactions or suffocation due to oropharyngeal edema is possible. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A cold stimulation test confirms the diagnosis in most patients (",
"      <a class=\"graphic graphic_picture graphicRef55636 \" href=\"UTD.htm?26/31/27123\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of cold urticaria are idiopathic, although a minority is related to another underlying disorder, such as cryoglobulinemia. (See",
"      <a class=\"local\" href=\"#H1485884\">",
"       'Laboratory tests to exclude other disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Avoidance of cold exposure is the best prophylaxis. However, complete avoidance is difficult for most patients. Patients should be educated about high-risk activities and situations, such as swimming, surgery, and ingestion of cold foods and beverages. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We prescribe epinephrine autoinjectors for those patients with a history of anaphylaxis, systemic symptoms, frequent or unavoidable cold exposure,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a high temperature threshold. We advise such patients to carry epinephrine at all times and periodically review how and when to administer it. (See",
"      <a class=\"local\" href=\"#H1486254\">",
"       'Epinephrine for systemic symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend nonsedating, second generation H1 antihistamines for patients with cold urticaria who are unable to sufficiently avoid cold exposure and have frequent symptoms (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We typically begin with the standard dose and increase up to four times this dose, as needed to control symptoms. (See",
"      <a class=\"local\" href=\"#H1487514\">",
"       'H1 antihistamines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/1\">",
"      M&ouml;ller A, Henning M, Zuberbier T, Czarnetzki-Henz BM. [Epidemiology and clinical aspects of cold urticaria]. Hautarzt 1996; 47:510.",
"     </a>",
"    </li>",
"    <li>",
"     Moller A, Henz BM. Cold urticaria. In: Urticaria: Clinical, diagnostic, and therapeutic aspects, Henz BM, Zuberbier T, Grabbe J, Monroe E (Eds), Springer, Berlin 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/3\">",
"      Katsarou-Katsari A, Makris M, Lagogianni E, et al. Clinical features and natural history of acquired cold urticaria in a tertiary referral hospital: a 10-year prospective study. J Eur Acad Dermatol Venereol 2008; 22:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/4\">",
"      Moreno JN, Harfi HA. Cold urticaria in Saudi Arabia. Ann Allergy 1989; 63:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/5\">",
"      Neittaanm&auml;ki H. Cold urticaria. Clinical findings in 220 patients. J Am Acad Dermatol 1985; 13:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/6\">",
"      Wanderer AA, Grandel KE, Wasserman SI, Farr RS. Clinical characteristics of cold-induced systemic reactions in acquired cold urticaria syndromes: recommendations for prevention of this complication and a proposal for a diagnostic classification of cold urticaria. J Allergy Clin Immunol 1986; 78:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/7\">",
"      Alangari AA, Twarog FJ, Shih MC, Schneider LC. Clinical features and anaphylaxis in children with cold urticaria. Pediatrics 2004; 113:e313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/8\">",
"      Kaplan AP, Garofalo J, Sigler R, Hauber T. Idiopathic cold urticaria: in vitro demonstration of histamine release upon challenge of skin biopsies. N Engl J Med 1981; 305:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/9\">",
"      Kaplan AP, Gray L, Shaff RE, et al. In vivo studies of mediator release in cold urticaria and cholinergic urticaria. J Allergy Clin Immunol 1975; 55:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/10\">",
"      Wanderer AA, Hoffman HM. The spectrum of acquired and familial cold-induced urticaria/urticaria-like syndromes. Immunol Allergy Clin North Am 2004; 24:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/11\">",
"      Gruber BL, Baeza ML, Marchese MJ, et al. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988; 90:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/12\">",
"      Nilsson T, B&auml;ck O. On the role of the C1-esterase inhibitor in cold urticaria. Acta Derm Venereol 1984; 64:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/13\">",
"      Wasserman SI, Ginsberg MH. Release of platelet factor 4 into the blood after cold challenge of patients with cold urticaria. J Allergy Clin Immunol 1984; 74:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/14\">",
"      Grandel KE, Farr RS, Wanderer AA, et al. Association of platelet-activating factor with primary acquired cold urticaria. N Engl J Med 1985; 313:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/15\">",
"      Stafford CT, Jamieson DM. Cold urticaria associated with C4 deficiency and elevated IgM. Ann Allergy 1986; 56:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/16\">",
"      Petit A, Schnitzler L, Lassoued K, et al. Anti-lamin-B autoantibodies in a patient with cold urticaria. Dermatology 1992; 185:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/17\">",
"      Lemanske RF Jr, Bush RK. Cold urticaria in infectious mononucleosis. JAMA 1982; 247:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/18\">",
"      Doeglas HM, Rijnten WJ, Schr&ouml;der FP, Schirm J. Cold urticaria and virus infections: a clinical and serological study in 39 patients. Br J Dermatol 1986; 114:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/19\">",
"      Lin RY, Schwartz RA. Cold urticaria and HIV infection. Br J Dermatol 1993; 129:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/20\">",
"      Kr&auml;nke B, Mayr-Kanh&auml;user S, Aberer W. Helicobacter pylori in acquired cold urticaria. Contact Dermatitis 2001; 44:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/21\">",
"      Miralles L&oacute;pez JC, L&oacute;pez Andreu FR, S&aacute;nchez-Gasc&oacute;n F, et al. Cold urticaria associated with acute serologic toxoplasmosis. Allergol Immunopathol (Madr) 2005; 33:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/22\">",
"      Doeglas HM. Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias. Br J Dermatol 1975; 93:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/23\">",
"      Kalogeromitros D, Gregoriou S, Papaioannou D, et al. Acquired primary cold contact urticaria after Hymenoptera sting. Clin Exp Dermatol 2004; 29:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/24\">",
"      Siebenhaar F, Weller K, Mlynek A, et al. Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol 2007; 32:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/25\">",
"      Mathelier-Fusade P, A&iuml;ssaoui M, Bakhos D, et al. Clinical predictive factors of severity in cold urticaria. Arch Dermatol 1998; 134:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/26\">",
"      Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006; 61:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/27\">",
"      B&auml;ck O, Larsen A. Delayed cold urticaria. Acta Derm Venereol 1978; 58:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/28\">",
"      Matthews CN, Warin RP. Delayed cold urticaria. Br J Dermatol 1977; 97 Suppl 15:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/29\">",
"      Gandhi C, Healy C, Wanderer AA, Hoffman HM. Familial atypical cold urticaria: description of a new hereditary disease. J Allergy Clin Immunol 2009; 124:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/30\">",
"      Ombrello MJ, Remmers EF, Sun G, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 2012; 366:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/31\">",
"      Kaplan AP. Unusual cold-induced disorders: cold-dependent dermatographism and systemic cold urticaria. J Allergy Clin Immunol 1984; 73:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/32\">",
"      Matthews CN, Warin RP. Cold urticaria and cold precipitated dermographism. Br J Dermatol 1970; 82:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/33\">",
"      Kaplan AP, Garofalo J. Identification of a new physically induced urticaria: cold-induced cholinergic urticaria. J Allergy Clin Immunol 1981; 68:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/34\">",
"      Wanderer AA. Cold urticaria syndromes: historical background, diagnostic classification, clinical and laboratory characteristics, pathogenesis, and management. J Allergy Clin Immunol 1990; 85:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/35\">",
"      Sciallis GF 2nd, Krych EH. Localized cold urticaria to the face in a pediatric patient: a case report and literature review. Pediatr Dermatol 2010; 27:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/36\">",
"      Kurtz AS, Kaplan AP. Regional expression of cold urticaria. J Allergy Clin Immunol 1990; 86:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/37\">",
"      Czarnetzki BM, Frosch PJ, Sprekeler R. Localized cold reflex urticaria. Br J Dermatol 1981; 104:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/38\">",
"      Ting S, Mansfield LE. Localized cold-reflex urticaria. J Allergy Clin Immunol 1985; 75:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/39\">",
"      Siebenhaar F, Staubach P, Metz M, et al. Peltier effect-based temperature challenge: an improved method for diagnosing cold urticaria. J Allergy Clin Immunol 2004; 114:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/40\">",
"      Magerl M, Borzova E, Gim&eacute;nez-Arnau A, et al. The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy 2009; 64:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/41\">",
"      Wanderer AA, St Pierre JP, Ellis EF. Primary acquired cold urticaria. Double-blind comparative study of treatment with cyproheptadine, chlorpheniramine, and placebo. Arch Dermatol 1977; 113:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/42\">",
"      Mlynek A, B&auml;r M, Bauer A, Meurer M. Juvenile pemphigus foliaceus associated with severe nonscarring alopecia. Br J Dermatol 2009; 161:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/43\">",
"      Mynek A, Magerl M, Siebenhaar F, et al. Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. Br J Dermatol 2010; 162:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/44\">",
"      Booth K, Parissis H. Management of cold-induced urticaria during cardiac surgery. J Card Surg 2011; 26:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/45\">",
"      De la Borbolla JM, Tapies S, Mbongo C, et al. Cold urticaria: its importance in the operating room. J Investig Allergol Clin Immunol 2010; 20:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/46\">",
"      La Shell MS, Tankersley MS, Kobayashi M. Cold urticaria: a case report and review of the literature. Cutis 2005; 76:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/47\">",
"      Bird JA, Burks W. Peanut allergy saves a patient with cold-induced hypotension and urticaria. J Pediatr 2010; 156:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/48\">",
"      Magerl M, Schmolke J, Siebenhaar F, et al. Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy 2007; 62:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/49\">",
"      Siebenhaar F, Degener F, Zuberbier T, et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009; 123:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/50\">",
"      Metz M, Scholz E, Ferr&aacute;n M, et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol 2010; 104:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/51\">",
"      Villas Mart&iacute;nez F, Contreras FJ, L&oacute;pez Caza&ntilde;a JM, et al. A comparison of new nonsedating and classical antihistamines in the treatment of primary acquired cold urticaria (ACU). J Investig Allergol Clin Immunol 1992; 2:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/52\">",
"      Magerl M, Pisarevskaja D, Staubach P, et al. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1) -antihistamine dose escalation. Br J Dermatol 2012; 166:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/53\">",
"      Visitsunthorn N, Tuchinda M, Vichyanond P. Cold urticaria in Thai children: comparison between cyproheptadine and ketotifen in the treatment. Asian Pac J Allergy Immunol 1995; 13:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/54\">",
"      Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006; 61:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/55\">",
"      Duc J, P&eacute;coud A. Successful treatment of idiopathic cold urticaria with the association of H1 and H2 antagonists: a case report. Ann Allergy 1986; 56:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/56\">",
"      Bonadonna P, Lombardi C, Senna G, et al. Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. J Am Acad Dermatol 2003; 49:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/57\">",
"      Hani N, Hartmann K, Casper C, et al. Improvement of cold urticaria by treatment with the leukotriene receptor antagonist montelukast. Acta Derm Venereol 2000; 80:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/58\">",
"      Nuutinen P, Harvima IT, Ackermann L. Histamine, but not leukotriene C4, is an essential mediator in cold urticaria wheals. Acta Derm Venereol 2007; 87:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/59\">",
"      Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006; 117:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/60\">",
"      Metz M, Altrichter S, Ardelean E, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011; 154:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/61\">",
"      Marsland AM, Beck MH. Cold urticaria responding to systemic ciclosporin. Br J Dermatol 2003; 149:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/62\">",
"      T&oacute;th-K&aacute;sa I, Jancs&oacute; G, Ob&aacute;l F Jr, et al. Involvement of sensory nerve endings in cold and heat urticaria. J Invest Dermatol 1983; 80:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/63\">",
"      Raap U, Liekenbr&ouml;cker T, Wieczorek D, et al. [New therapeutic strategies for the different subtypes of urticaria]. Hautarzt 2004; 55:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/64\">",
"      Black AK, Eady RA, Greaves MW, et al. Treatment of acquired cold urticaria by prednisone: dissociation of histamine release and clinical improvement [proceedings]. Br J Clin Pharmacol 1980; 9:116P.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/65\">",
"      Claudy A. Cold urticaria. J Investig Dermatol Symp Proc 2001; 6:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/66\">",
"      Black AK, Sibbald RG, Greaves MW. Cold urticaria treated by induction of tolerance. Lancet 1979; 2:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/67\">",
"      von Mackensen YA, Sticherling M. Cold urticaria: tolerance induction with cold baths. Br J Dermatol 2007; 157:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15721/abstract/68\">",
"      Kring Tannert L, Stahl Skov P, Bjerremann Jensen L, et al. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction. Dermatology 2012; 224:101.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8102 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-210.101.131.232-3CA5444EA1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15721=[""].join("\n");
var outline_f15_22_15721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4450715\">",
"      Associated disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23479940\">",
"      Cutaneous signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23479947\">",
"      Systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4451196\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3768741\">",
"      Variant forms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23480286\">",
"      Cold stimulation tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23480071\">",
"      - Ice cube test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4448940\">",
"      - Specialized testing devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23480244\">",
"      - Cold packs and cold water baths",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1727555\">",
"      - Natural exposure testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1485884\">",
"      Laboratory tests to exclude other disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23480278\">",
"      Threshold testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10165653\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4449202\">",
"      Education about high-risk activities and cold avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3768893\">",
"      Treatment of acute signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1486254\">",
"      - Epinephrine for systemic symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3768986\">",
"      - Treatment of milder symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3768840\">",
"      Preventative therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1487514\">",
"      - H1 antihistamines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4449650\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cold desensitization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8102\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8102|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/36/21058\" title=\"picture 1\">",
"      Urticaria 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/31/27123\" title=\"picture 2\">",
"      Physical urticaria B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/4/19522\" title=\"picture 3\">",
"      TempTest temp threshold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/37/5713\" title=\"picture 4\">",
"      TempTest stim time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8102|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/35/34364\" title=\"table 1\">",
"      Physical urticaria testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9401?source=related_link\">",
"      Anaphylaxis: Confirming the diagnosis and determining the trigger(s)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=related_link\">",
"      Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=related_link\">",
"      Chronic urticaria: Standard management and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30554?source=related_link\">",
"      Chronic urticaria: Treatment of refractory symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33672?source=related_link\">",
"      Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7576?source=related_link\">",
"      Cryofibrinogenemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=related_link\">",
"      Paroxysmal cold hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/27/44466?source=related_link\">",
"      Patient information: Physical hives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=related_link\">",
"      Physical urticarias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_22_15722="Thrombosis associated with chronic hemodialysis vascular access: Catheters";
var content_f15_22_15722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thrombosis associated with chronic hemodialysis vascular access: Catheters",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/22/15722/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15722/contributors\">",
"     Gerald A Beathard, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/22/15722/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15722/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15722/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/22/15722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/22/15722/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/22/15722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of tunneled catheters for vascular access for hemodialysis is associated with a relatively high incidence of complications. The most frequently occurring complication is catheter dysfunction or poor flow [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/1\">",
"     1",
"    </a>",
"    ]. In general, this is taken to be a blood flow less than 300",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/2\">",
"     2",
"    </a>",
"    ]. In reality, however, this level is too low.",
"   </p>",
"   <p>",
"    A catheter that is not able to deliver at least 400",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    should be evaluated for dysfunction, for some of the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most instances, the patient's dialysis prescription calls for a blood flow rate of at least 400",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      Given that catheter designs are readily available that can provide blood flow of more than 400",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      their potential should be utilized if required by the dialysis prescription.",
"     </li>",
"     <li>",
"      Catheter dysfunction is progressive. If a catheter capable of providing a blood flow of 400",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      is only able to allow for a flow of 300",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      the progressive pathogenic process has begun.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Catheter dysfunction may be classified as early or late [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/3\">",
"     3",
"    </a>",
"    ]. This time distinction is important because the etiology for the problems that result in these two categories is different. Early catheter failure is defined as that which occurs immediately. In other words, the catheter never functioned adequately (ie, did not deliver the expected blood flow of &ge;400",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"   </p>",
"   <p>",
"    By comparison, late dysfunction is defined as a catheter that initially functioned in an optimal fashion, but then became dysfunctional. Such difficulties are usually due to thrombosis.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and management of thrombosis associated with chronic dialysis catheters will be reviewed here. The treatment of thrombosis in arteriovenous fistulas and grafts is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16727?source=see_link\">",
"     \"Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7942?source=see_link\">",
"     \"Strategies other than treatment of stenosis to prevent thrombosis of hemodialysis vascular access grafts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY CATHETER FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to reviewing the clinical features and management of catheter-related thrombosis, a brief discussion of the causes and treatment of inadequate blood flow that occur immediately after catheter insertion will be presented.",
"   </p>",
"   <p>",
"    In general, the problems that result in early failure are related to catheter position or technical problems with placement. Under the heading of improper positioning are catheter tip malorientation, tip malposition, and placement into the wrong vessel, for example the azygous vein. Technical problems that can result in early failure include a kinked catheter and sutures that are constrictive. If the newly placed catheter was an exchange of a previously malfunctioning one, replacement of the catheter into a pre-existing fibrin sheath must also be considered as a possible cause.",
"   </p>",
"   <p>",
"    With a high frequency of central vein stenosis and occlusion occurring in patients who have had hemodialysis catheters, enlargement of the azygous vein due to increased flow from collateral drainage is common. In these cases, placement of a catheter into the azygous is not unusual. This can be recognized easily by looking at the angle of the catheter in the mediastinum. The axis of the superior vena cava, right atrium, inferior vena cava is vertical, parallel to the long axis of the mediastinum. When inserted, if the catheter or a guidewire runs obliquely toward the midline when viewed in an A-P presentation, placement into the azygous should be suspected.",
"   </p>",
"   <p>",
"    Malposition leading to early failure can also result from retraction of the catheter. Cuffed catheters move up and down within the vein, and in and out at the anatomic location where the catheter enters the vein. Part of catheter retraction is due to the fact that when an individual goes from a supine position (as with catheter placement) to an upright position (as with dialysis), the abdomen has a tendency to bulge outward, causing the diaphragm to be pulled downward. This causes a lengthening of the mediastinum. Since the catheter is attached at the cuff (skin level), it retracts.",
"   </p>",
"   <p>",
"    This movement also occurs in patients with large breasts or a thick layer of fat on their chest at the exit site where the catheter is attached by the cuff. When the individual goes from the supine to the erect position, this excess tissue sags, pulling the catheter exit site (where cuff is attached) downward with it. This retraction can result in a catheter tip which is in excellent position at the time of placement when the patient is supine, but in a very poor position when the patient is sitting",
"    <strong>",
"     up",
"    </strong>",
"    , as during hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problems that result in early catheter failure should be recognized and corrected at the time of catheter placement. Fluoroscopy is critical to this purpose. It should be considered mandatory for the placement of all chronic dialysis catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/4\">",
"     4",
"    </a>",
"    ]. Because of retraction, the tunneled catheter's tip should be placed well within the atrium at the time of insertion using fluoroscopic guidance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LATE CATHETER DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late catheter dysfunction is generally the result of partial or total thrombosis. Catheter thrombosis is a common problem, frequently resulting in catheter loss (the mean patency rate ranges from 73 to 84 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The specific factors leading to thrombosis in an individual case are seldom obvious. The patient with a definable hypercoagulable state, for example, is rarely observed.",
"   </p>",
"   <p>",
"    Catheter-related thrombosis can be classified as either extrinsic or intrinsic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/3\">",
"     3",
"    </a>",
"    ]. An extrinsic thrombus is one that forms outside of the catheter and is not necessarily attached to it, although the catheter or its tip may be embedded within the thrombus. An intrinsic thrombus is one that either forms within the catheter or completely surrounds it as a sleeve or sheath.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Extrinsic catheter-related thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three types of extrinsic thrombi:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Axillo-subclavian vein thrombosis &mdash; The presence of a catheter within the central veins, most commonly the subclavian, can precipitate thrombosis within the vessel.",
"     </li>",
"     <li>",
"      Mural thrombus &mdash; This type of thrombus forms on the wall of the vein or the atrium at the point of its contact with the tip of the catheter.",
"     </li>",
"     <li>",
"      Large intra-atrial thrombus &mdash; This thrombus presents as a mass within the right atrium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All forms of extrinsic thrombi can, in addition to causing catheter blood flow problems during hemodialysis, present with relatively unique clinical features that suggest the particular type of thrombus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Axillo-subclavian vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency with which a catheter within the central veins precipitates thrombosis of the vein is unclear. Some investigators have found that it is uncommon, occurring in only 2 percent in a series of 101 percutaneously inserted catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/7\">",
"     7",
"    </a>",
"    ]. By comparison, another study of 63 patients with central venous catheters (but not dialysis catheters) reported an incidence of 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/8\">",
"     8",
"    </a>",
"    ]; in this report, the authors evaluated the patients systematically after catheter removal. Since most of these thrombi are asymptomatic (see below), it appears that the frequency with which central vein thrombosis is discovered is related to the frequency with which it is searched for in asymptomatic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35800822\">",
"    <span class=\"h4\">",
"     Symptomatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;When symptomatic thrombosis of the axillo-subclavian vein occurs, the symptoms can be dramatic, with the diagnosis based primarily upon, in addition to poor access flow, clinical symptoms and findings that are frequently florid. Locally, the thrombus incites an inflammatory reaction with pain and tenderness at the base of the neck, the supraclavicular fossa, and the shoulder area. Obstruction of the thoracic veins may lead to edema of the arm and hand. This is often exercise-dependent, being present only when the arm is used vigorously. In some patients, the edema is only a subjective symptom, presenting as a feeling of fullness in the fingers or difficulty with finger rings feeling \"too tight.\"",
"   </p>",
"   <p>",
"    Signs and symptoms of embolization are unusual. There have not been studies that accurately report the incidence of embolization from axillo-subclavian thrombosis associated with dialysis catheters. Pulmonary embolization represents a very significant complication observed with primary or spontaneous axillo-subclavian thrombosis (Paget-von Scrotter syndrome); however, the mechanism and pathophysiology is completely different.",
"   </p>",
"   <p>",
"    It has been observed that as the use of central venous catheters increased starting in the 1970s, the relative incidence of axillo-subclavian thrombosis increased, the etiology shifted from primary (spontaneous) to catheter related and the incidence of associated embolization decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Anecdotally, embolization is a rare occurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35800829\">",
"    <span class=\"h5\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the signs and symptoms of symptomatic thrombosis are diagnostic, it may be desirable to document the diagnosis by more objective means in some cases. Digital subtraction angiography is the most sensitive and specific technique for demonstrating the presence of axillo-subclavian vein thrombosis and is considered the reference gold standard [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/11,13-16\">",
"     11,13-16",
"    </a>",
"    ]. However, it has the disadvantage of being invasive and requiring cannulation of either a peripheral vein or the patient's access. In many instances, edema of the arm can make this difficult. It is also more expensive than ultrasonography.",
"   </p>",
"   <p>",
"    Duplex ultrasonography has emerged as the study of choice should confirmation be required. Results of some of the studies that examined the accuracy of this technique are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective report evaluated 44 patients with subclavian venous catheters in an attempt to establish a correlation between color Doppler ultrasound observations and venography in detecting catheter-related thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/17\">",
"       17",
"      </a>",
"      ]. Criteria considered as showing the presence of catheter-related thrombosis included visualization of thrombus (T), absence of spontaneous flow (S), absence of phasicity of flow with respiration (P), incompressibility of the vein with probe pressure (C), and visualization of increased venous collaterals (V). Analyzing each variable separately, P had the highest sensitivity (94 percent) and S had the highest specificity (100 percent). The best combinations for diagnosis were T+P, P+S, and T+P+S, which had a sensitivity of 94 percent and specificity of 88 percent. Overall, the diagnostic value of color Doppler ultrasonography had a sensitivity and specificity of 94 and 96 percent, respectively.",
"     </li>",
"     <li>",
"      In another study, 60 upper extremities in 42 hemodialysis patients, the efficacy of color flow duplex imaging in detecting proximal upper extremity venous outflow obstruction was compared with that of traditional contrast venography [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/18\">",
"       18",
"      </a>",
"      ]. Five (8 percent) of the 60 duplex scans were non-diagnostic because of artifact from intravenous dialysis catheters (3) or incomplete visualization of the subclavian or brachiocephalic veins (2). In the remaining 55 duplex scans, proximal venous outflow obstruction was found in 18 (33 percent), compared with 21 (38 percent) identified by means of venography. Overall sensitivity, specificity, positive predictive value, and negative predictive value for color flow duplex imaging were 81, 97, 94, and 89 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subclavian vein thrombi not visualized by duplex ultrasonography are usually either nonocclusive mural thrombi or thrombi located in the proximal part of the vein possibly shadowed by the clavicle and sternum [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/19\">",
"     19",
"    </a>",
"    ]. By observing ancillary features such as flow, phasicity and compressibility of the vein, the sensitivity of this test can be considerably enhanced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35800836\">",
"    <span class=\"h5\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;When symptomatic thrombosis is present, the catheter should be removed if possible. This alone may be sufficient to obtain resolution of symptoms in most cases. Anticoagulation has become the mainstay of therapy for these patients, although controlled studies have not been conducted to evaluate its effectiveness. It is recommended that the patient receive anticoagulation for a period of three months after catheter removal to prevent extension of the thrombus and to allow it to organize.",
"   </p>",
"   <p>",
"    Initially, severely symptomatic patients with axillo-subclavian thrombosis should be treated with a five to seven day course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low-molecular-weight heparin (LMWH). The advantage to LMWH is that it can be administered in the outpatient setting. However, patients with severe symptoms, significant concomitant medical illness, or a high risk for bleeding should be treated in the hospital. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=see_link\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral anticoagulants can be started within 24 hours of the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or LMWH.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    should be started at a dose of 5 mg with subsequent doses adjusted to achieve an International Normalized Ratio (INR) of 2.0 to 3.0. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .) If there is no contraindication to their use, thrombolytic therapy may be considered for patients with extensive thrombosis.",
"   </p>",
"   <p>",
"    In cases in which potential sites for vascular access are depleted or extremely limited, it may be possible to preserve the catheter. However, if this strategy is chosen, the patient should be systemically anticoagulated and observed very closely. The presence of the catheter can promote the development of infection, with an infected axillo-subclavian vein thrombus frequently resulting in disastrous consequences, such as septic emboli.",
"   </p>",
"   <p>",
"    The use of thrombolytics frequently arises in the management of these cases. This has been felt to be useful in cases of primary axillo-subclavian thrombosis (Paget-von Schr&ouml;tter syndrome). However, its value in these secondary dialysis catheter related cases has not been proven. In a retrospective study, 95 consecutive inpatients with axillo-subclavian vein thrombosis were treated either with systemic urokinase thrombolysis and subsequent oral anticoagulation (n = 33) or with anticoagulation only (n = 62) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/20\">",
"     20",
"    </a>",
"    ]. Systemic thrombolysis had an acceptable primary technical success rate and improved venous recanalization rates compared to anticoagulation alone. However, a high rate of complications during thrombolysis was observed and there was a lack of long-term clinical benefit.",
"   </p>",
"   <p>",
"    The authors suggested that conservative treatment might be favored in this condition. However, these were not dialysis patients. In the dialysis patient, the preservation of subclavian vein patency might outweigh the risk of complications inherent with the use of thrombolytic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35800857\">",
"    <span class=\"h4\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, most thrombotic events of axillo-subclavian veins are clinically asymptomatic. Thus, the existence of a thrombus, such as a subclavian vein thrombosis, must be suggested by other means. The presence of dilated chest wall veins, often unilateral, during an unrelated examination can be the initial manifestation. In other patients, signs and symptoms of embolization, either to the pulmonary circulation or paradoxically to the systemic arterial bed, may be the first clue.",
"   </p>",
"   <p>",
"    Once asymptomatic thrombosis is suspected, the same techniques effective in the diagnosis of symptomatic thrombi should be employed. However, duplex ultrasound has a lower sensitivity in this setting, making a negative study fairly noncontributory to patient care. Fortunately, its specificity remains quite high and the test is easy to perform. As a result, duplex ultrasound is recommended as the initial screening tool. In the event of a negative ultrasound study, venography is the only reliable way to make or exclude the diagnosis.",
"   </p>",
"   <p>",
"    The overall treatment of the asymptomatic patient should be dictated by the extent of disease. However, if axillo-subclavian thrombosis of any degree is diagnosed with a reasonable degree of certainty, the patient should be managed in the same manner as a symptomatic case. There is a close association between venous stenosis and thrombosis in these cases. Although most cases of stenosis are not associated with a thrombus, the reverse is not the case. Obviously, if only an anatomical lesion is present, treatment with pharmacological agents is not indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Mural thrombus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroscopic observation of a tunneled catheter in place reveals that it is in constant motion due to the movement of the heart. Movement of the catheter tip may cause damage to the wall of the vessel or the atrium, resulting in mural thrombus formation at the point of contact [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The tip of the catheter generally becomes embedded in this thrombus, causing catheter malfunction.",
"   </p>",
"   <p>",
"    Most mural thrombi are not recognized unless there is catheter malfunction. The diagnosis is generally made with venography performed through the catheter. Larger mural thrombi may be symptomatic and can result in pulmonary embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/24\">",
"     24",
"    </a>",
"    ]. These larger thrombi can be detected by transesophageal echocardiography.",
"   </p>",
"   <p>",
"    When recognized, removal of the catheter is indicated, which alone represents adequate treatment for small thrombi. Their primary clinical significance is catheter dysfunction. Patients with larger thrombi, such as those detected by transesophageal echocardiography, should be anticoagulated as described above for symptomatic axillo-subclavian vein thrombi; they should be followed by repeat echocardiographic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/21\">",
"     21",
"    </a>",
"    ]. If a large mural thrombus becomes infected, it can lead to disastrous results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Intra-atrial thrombus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Size is important when dealing with an intra-atrial thrombus. A ball thrombus of two cm or less is not felt to be of clinical importance. By comparison, larger thrombi can have serious consequences depending upon their size.",
"   </p>",
"   <p>",
"    When the thrombus attached to the tip of the catheter is small (less than 2 cm), there does not appear to be a problem in simply pulling the catheter, although some nephrologists feel that systemic anticoagulation for a few weeks prior to catheter removal is of value. Either way, these small thrombi do not appear to pose a serious problem.",
"   </p>",
"   <p>",
"    A large intra-atrial thrombus (greater than 2 cm) is a rare complication of a hemodialysis catheter, only approximately 49 have been reported in the medical literature [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/25\">",
"     25",
"    </a>",
"    ]. It may present as hemodialysis catheter dysfunction, systemic infection, pulmonary or (paradoxical) systemic emboli, or a mass within the right atrium (as observed angiographically or by echocardiography) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/24,26,27\">",
"     24,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large intra-atrial thrombi can have serious consequences. In one study, for example, four of five cases of atrial thrombus were diagnosed during the investigation of hemoptysis or dyspnea in patients receiving dialysis via a tunneled catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/28\">",
"     28",
"    </a>",
"    ]. In the fifth patient, a screening transthoracic echocardiogram revealed the thrombus. Three of the five patients developed pulmonary emboli, and a fourth had an unexplained electromechanical dissociation cardiac arrest without definite evidence of pulmonary embolus. Appreciable mortality was noted in a larger series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been no controlled studies to define the optimal treatment for large (greater than 2 cm) atrial thrombi. With this understanding, there have been a series of anecdotal case reports and proposals for therapy that are presented below.",
"   </p>",
"   <p>",
"    The presence of a 2 cm or larger thrombus may be heralded by catheter dysfunction, symptoms and signs of pulmonary emboli, and symptoms suggestive of endocarditis or syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/24\">",
"     24",
"    </a>",
"    ]. The choice of therapy should be determined by the clinical setting. If the patient is experiencing pulmonary emboli, the thrombus is infected, or if its size is such that it is causing mechanical problems with cardiac function, catheter removal combined with simultaneous immediate surgical thrombectomy should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/24,26,28,29\">",
"     24,26,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients who only have catheter dysfunction and the incidental discovery of a large right atrial thrombus, there are multiple choices for treatment: catheter removal with prolonged anticoagulation, thrombolysis followed by catheter removal, simultaneous catheter removal and immediate surgical thrombectomy, and simple catheter removal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is asymptomatic and the thrombus is not infected, catheter removal with prolonged anticoagulation is a reasonable approach [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/25\">",
"       25",
"      </a>",
"      ]. In one study of 12 patients with this problem, chronic anticoagulation for six months lead to complete resolution in 50 percent of the cases [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/30\">",
"       30",
"      </a>",
"      ]. Anticoagulation should be conducted as described above for symptomatic axillo-subclavian thrombi, but should be continued until the thrombus resolves or becomes stable (some investigators recommend at least six months) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/26\">",
"       26",
"      </a>",
"      ]. The progress of the thrombus should be monitored by echocardiography performed at weekly intervals until the thrombus resolves or becomes stable. However, even anticoagulated patients remain at risk for pulmonary emboli [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are no published studies on the use of thrombolytic therapy of a large right atrial thrombus specifically associated with a dialysis catheter. However, there are several reports of successful thrombolytic therapy for intra-atrial thrombi associated with other types of catheters and other types of situations [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/31-35\">",
"       31-35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of data derived from six new cases and 16 cases that had been previously published, catheter removal followed by surgical thrombectomy was associated with a lower mortality rate than catheter removal followed by prolonged anticoagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/26\">",
"       26",
"      </a>",
"      ]. However, most of the deaths were associated with bacteremia. Surgical thrombectomy in a stable asymptomatic patient does not seem to be appropriate until more conservative therapy has been tried.",
"     </li>",
"     <li>",
"      Simple catheter removal in the presence of a large right atrial thrombus has been associated with significant problems and should be",
"      <strong>",
"       avoided",
"      </strong>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intrinsic catheter-related thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrinsic thrombosis represents the principal complication associated with hemodialysis catheters and is the major cause of catheter loss. There are three types of intrinsic thrombi:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraluminal thrombosis &mdash; This term refers to a thrombus that occurs within the catheter lumen.",
"     </li>",
"     <li>",
"      Catheter tip thrombosis &mdash; This refers to a catheter related thrombus which develops at the tip of the catheter and is attached at that point.",
"     </li>",
"     <li>",
"      Fibrin sheath thrombus &mdash; This term refers to a thrombus that develops as a sleeve surrounding the catheter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intraluminal thrombus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraluminal thrombosis occurs when a thrombus forms within the catheter lumen. The likelihood is that this complication results from one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An inadequate volume of anticoagulant being placed within the catheter lumen",
"     </li>",
"     <li>",
"      Failure to close the clamp on the catheter before the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      syringe is detached",
"     </li>",
"     <li>",
"      Anticoagulant being lost from the catheter between dialysis treatments",
"     </li>",
"     <li>",
"      The presence of blood within the catheter",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When an intraluminal thrombus occurs, the catheter becomes totally occluded. The key to prevention is the adoption of a sound procedure for catheter maintenance. At the end of dialysis, this should consist of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forcibly flushing both lumens of the catheter with saline to completely clear them of all blood. (The usual rinse back with saline done at the end of dialysis is important to clear blood from the blood lines and dialyzer. It is actually not very efficient in completely clearing all blood from the catheter or dislodging any small thrombi that might be present).",
"     </li>",
"     <li>",
"      Carefully observing the fill volume for each lumen of the catheter to determine the volume of anticoagulant solution to use as a lock for each",
"     </li>",
"     <li>",
"      Being very careful to always close the clamp on the catheter before removing the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      syringe",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At the beginning of dialysis, each side of the catheter should be forcibly flushed with saline after the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    lock has been extracted. This type of thrombus is not very common when routine catheter maintenance techniques are applied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Catheter tip thrombus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the portion of the dialysis catheter from the side holes to the tip do not retain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , a thrombus can form in this location. A tip thrombus may be occlusive or act as a ball valve.",
"   </p>",
"   <p>",
"    Preventive measures that are used to avoid intraluminal thrombosis are generally adequate for the prevention of these thrombi. It is probable that forcible flushing before and after dialysis aids in clearing poorly attached catheter tip thrombi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Fibrin sheath thrombus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrin sheath thrombus is the most common thrombus that forms in association with the chronic dialysis catheter. It is therefore the most common cause of catheter dysfunction. All central venous catheters likely become encased in a layer of fibrin within a few days of insertion. As an example, in one autopsy study of 55 patients with central venous catheters, a fibrin sheath was found in 100 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term, fibrin sheath, refers to a sleeve that surrounds the intravenous portion of the catheter. Animal studies have suggested that this sheath is actually not composed entirely of fibrin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. When the vein is cannulated, the endothelium is injured and a thrombus forms around the catheter at the insertion site. This becomes organized and is eventually converted to fibroepithelial tissue. Fibrin continues to be deposited at the leading edge of this tissue and consequently becomes organized. In this manner, a sleeve of fibroepithelial tissue migrates down the catheter to form a sheath. Histologic studies have shown a transition as one moves down the catheter toward the tip from connective tissue to an area combined with thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This process has also been described in an autopsy report of a dialysis patient having a catheter in place for three years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/39\">",
"     39",
"    </a>",
"    ]. It appears that the fibroepithelial sleeve surrounding the catheter starts peripherally at the exit site, continues through the subcutaneous tunnel and extends down over the intravenous portion of the catheter. As the sheath extends downwards, it eventually closes over the tip of the catheter. In this position, it can be disrupted by inward pressure to create a flap-valve that will allow injection but prevents withdrawal of blood and fluid.",
"   </p>",
"   <p>",
"    This sheath is only loosely attached to the catheter. When a catheter is removed, angiography performed through the partially retracted catheter can demonstrate a \"wind sock\" of residual fibrin sleeve in approximately 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not all fibrin sheaths are symptomatic. The reported incidence of catheter dysfunction secondary to this problem ranges between 13 to 57 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/6\">",
"     6",
"    </a>",
"    ]. Fibrin sheath formation generally causes catheter dysfunction weeks or months after catheter placement. However, it has been observed as early as 48 hours post placement.",
"   </p>",
"   <p>",
"    The question arises as to whether a fibrin sheath can lead to or contribute to the formation of a stenotic lesion within the vein. The answer to this question is not available. Histological studies of human autopsy material of long-term catheters have shown the development of vein wall thickening and bridges from the vein wall to the fibrin sheath covering the catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/22\">",
"     22",
"    </a>",
"    ]. As to whether this reaction may progress on to stenosis is not known. However, these types of changes have caused some interventionalists to question as to whether a fibrin sheath should be ablated even if the catheter is being permanently removed to minimize the risk of later developing venous stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT OF LATE DEVELOPING FLOW PROBLEMS DUE TO INTRINSIC THROMBUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late-developing catheters malfunction due to thrombosis (whether extrinsic or intrinsic) is practically defined as follows: the failure to attain and maintain an extracorporeal blood flow sufficient to perform hemodialysis without significantly lengthening the hemodialysis treatment in a catheter that was previously working adequately. Sufficient extracorporeal blood flow is considered to be 300",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/41\">",
"     41",
"    </a>",
"    ]. This definition is probably too conservative. With the catheters that are available today, the goal for optimal flow should be 400",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    Once",
"    recognized, catheter malfunction should be addressed immediately. Delayed treatment results in both inadequate dialysis and excessive catheter manipulation. Unfortunately, the later activity often leads to catheter-related bacteremia. A recommended approach to the management of extrinsic catheter-related thrombosis was discussed with the various types of thrombus described under that heading (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Extrinsic catheter-related thrombosis'",
"    </a>",
"    above). Treatment of intrinsic catheter-related thrombosis can be categorized as either primary (which can be immediately applied within the hemodialysis facility) or secondary (for which the patient has to be sent to referral facility) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Primary treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary treatment is therapy for catheter dysfunction that can be performed within a short time within the dialysis facility, allowing the patient to continue with their regularly scheduled dialysis treatment. Such therapies do not require a radiographic procedure and are therefore initiated empirically. Thus, they are initiated prior to an absolute diagnosis being established, with either an intrinsic or extrinsic thrombus being a possible underlying abnormality. The categories of primary treatment are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Forceful saline flush",
"     </li>",
"     <li>",
"      Intraluminal lytic enzyme",
"     </li>",
"     <li>",
"      Infusion of lytic enzyme",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Forceful saline flush",
"    </span>",
"    &nbsp;&mdash;&nbsp;A forceful flush should be the",
"    <strong>",
"     first",
"    </strong>",
"    approach to treatment of a malfunctioning catheter that has previously functioned adequately [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/3\">",
"     3",
"    </a>",
"    ]. The force that can be generated with a syringe is inversely proportional to the size of the syringe (it is actually related to the ratio of the diameter of the plunger to that of the syringe outlet opening). Thus, a small syringe should be used and should possess a Luer lock so that it will not become detached during the procedure. To minimize the chance of catheter rupture, the syringe should not be smaller than 5 mL; a 10 mL syringe is optimal.",
"   </p>",
"   <p>",
"    The syringe should be filled with saline, attached firmly to the catheter, and flushed into the catheter with as much force as can be generated with the hand. Once done, an attempt to aspirate blood should be made. If no blood can be aspirated, the saline flush can be repeated several times. If blood can be aspirated, the procedure should be repeated multiple times using blood until flow seems to be free and easy.",
"   </p>",
"   <p>",
"    The saline flush technique has the advantages of being easily performed, economical, safe, and frequently effective. Although a successful saline flush means that the thrombus that occluded the catheter has embolized, this does not appear to be a problem clinically since the thrombus is very small. Thrombi of this type and size are frequently embolized in catheter-dialyzed patients without being recognized.",
"   </p>",
"   <p>",
"    The disadvantages of this procedure are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It may not be successful.",
"     </li>",
"     <li>",
"      It is not a permanent solution.",
"     </li>",
"     <li>",
"      There is a small risk of rupturing the catheter. However, if the catheter does rupture, it is not a major problem. An intravascular rupture will not be obvious, although the catheter will continue to be dysfunctional. An extravascular rupture simply needs to be clamped central to the rupture until the catheter can be replaced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Intraluminal lytic enzyme",
"    </span>",
"    &nbsp;&mdash;&nbsp;The instillation of intraluminal lytic enzyme has been extremely useful to the nephrologist in managing catheter dysfunction within the dialysis facility. In the past, urokinase was used as the agent of choice for this purpose and was reasonably effective.",
"   </p>",
"   <p>",
"    However, tissue plasminogen activator (tPA) has replaced urokinase for this purpose and has been shown to be significantly more effective [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/13,42-48\">",
"     13,42-48",
"    </a>",
"    ]. Studies of catheter instillation with 1 mg (single treatment) to 2 mg (second treatment with another 1 mg) of tPA per lumen have reported short-term success in 83 to 98 percent of uses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/45,49\">",
"     45,49",
"    </a>",
"    ]. In a study of 995 patients, for example, occluded single (26 percent), double (39 percent), or triple (6 percent) lumen catheters or ports (29 percent) where treated with tPA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/47\">",
"     47",
"    </a>",
"    ]. Flow was successfully restored in 52 percent and 78 percent of catheters at 30 and 120 minutes after one dose, and 84 percent and 87 percent at 30 and 120 minutes after a second dose, respectively. Restoration of flow was 86 percent, 93 percent, 90 percent, and 79 percent, for single, double, and triple lumen catheters and ports, respectively. Estimated 30-day catheter patency was 74 percent. No complications were encountered.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     Tenecteplase",
"    </a>",
"    , another thrombolytic, can also significantly improve hemodialysis catheter function after intraluminal instillation. In one study, 149 patients with dysfunctional catheters were randomly assigned to receive a one hour intracatheter dwell with tenecteplase (2 mg) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/50\">",
"     50",
"    </a>",
"    ]. Compared with placebo, active therapy was associated with significant increases in percentage functional catheters (22 versus 5 percent) and mean change in blood flow rates (47 versus 12",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    Tenecteplase was well tolerated.",
"   </p>",
"   <p>",
"    In general, the effect of instilled tPA can be expected to be of only short term benefit, since the enzyme is only effective within the lumen and at the tip. It therefore does not come into contact with nor affect the bulk of the fibrin sheath, the most common cause of catheter dysfunction.",
"   </p>",
"   <p>",
"    Of critical importance is the primary patency of catheters following tPA treatment for dysfunction. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study involving only hemodialysis catheters, 85 episodes of catheter dysfunction were treated using tPA (Retavase, Centocor, Inc., Malvern, PA) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/46\">",
"       46",
"      </a>",
"      ]. The overall mean duration of catheter patency was 45",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      39 days.",
"     </li>",
"     <li>",
"      In a prospective study of only hemodialysis catheters, all uses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      in the setting of inadequate catheter blood flow in a cohort of 570 catheters over a 2.5-year period were analyzed [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/13\">",
"       13",
"      </a>",
"      ]. Alteplase instillation was necessary in 2.77 percent of dialysis sessions. The median time from the first to second treatment or catheter removal for nonfunction or thrombosis was 27 days (95 percent confidence interval, 15.7 to 32.3). Additional median survival advantage gained from each subsequent treatment ranged from 10 to 18 days. In other words, treatment of recurrent catheter malfunction with alteplase allowed for a median of only five to seven additional dialysis sessions before the treatment had to be repeated or the catheter exchanged. These authors suggested that the ultimate clinical benefit and cost-effectiveness of tPA treatment was doubtful because of the duration of the effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For practical reasons, it does seem that every dialysis facility should have a protocol in place for the use of tPA to open dysfunctional dialysis catheters. Such therapy can be accomplished with minimal disruption to the patient's dialysis schedule, which has value.",
"   </p>",
"   <p>",
"    However, the question as to how many times tPA should be used before the case is referred for a catheter exchange or whether it should be used at all is one that can be answered only in relationship to the circumstances of a given dialysis facility and the individual patient. The critical points are the patient's need for dialysis on a timely basis and the risks of excessive catheter manipulation. A catheter that is not able to provide the blood flow necessary for adequate dialysis according to the patient's prescription must not be tolerated. All catheter flow problems must be resolved in a timely fashion and the emphasis for managing catheter dysfunction should shift to intervention at a relatively early stage of dysfunction.",
"   </p>",
"   <p>",
"    Reasonable guidelines are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If lytic therapy is unable to restore blood flow to a level that will provide for adequate dialysis according to the patient's prescription, the catheter should be exchanged.",
"     </li>",
"     <li>",
"      If the duration of the effectiveness of lytic therapy is less than two weeks, serious consideration should be given to exchanging the catheter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Infusion of lytic enzyme",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of catheter thrombosis with transcatheter urokinase either as an infusion off of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/5,42\">",
"     5,42",
"    </a>",
"    ] or an infusion during dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/51,52\">",
"     51,52",
"    </a>",
"    ] has been used in the past with good success. Tissue plasminogen activator has been used in a similar manner. In one series, 55 cases of hemodialysis catheter malfunction felt to be related to fibrin sheath development were treated with tPA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/53\">",
"     53",
"    </a>",
"    ]. An infusion of 2.5 mg of tPA in 50 mL of normal saline was given as a 3-hour infusion though each port. The technical success rate, defined as at least one successful dialysis session, was 91 percent. A Kaplan-Meier survival analysis yielded primary patency rates at 30, 60, 90, and 120 days of 0.55, 0.36, 0.25, and 0.15, respectively. The dose of enzyme used was not large enough to result in systemic effects and no complications were encountered.",
"   </p>",
"   <p>",
"    Although in published reports, this type of therapy has been performed at a referral facility, it is listed as a primary treatment because there is no reason that it could not be accomplished in the dialysis clinic. However, the result obtained with this form of enzyme therapy is no better than that obtained with intra-luminal enzyme; in addition, it is more difficult and more expensive to accomplish. Its value is questionable and it is",
"    <strong>",
"     not recommended",
"    </strong>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Secondary treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the problem cannot be successfully resolved within the dialysis facility or if the treatment applied does not have an effect of sufficient duration, then the case should be referred to a secondary treatment facility for radiographic evaluation. Appropriate treatment should then be based upon the findings of this evaluation. The most commonly encountered problem is the fibrin sheath.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Catheter exchange over a guidewire",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter exchange over a guidewire can be safely and effectively used to eliminate intrinsic catheter thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/5,52,54\">",
"     5,52,54",
"    </a>",
"    ]. This procedure is the secondary",
"    <strong>",
"     treatment of choice",
"    </strong>",
"    for intrinsic catheter thrombosis.",
"   </p>",
"   <p>",
"    It is important to obliterate a fibrin sheath that has been detected before performing a catheter exchange over a guidewire.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 17 percent of the cases with early catheter failure in a large series of tunneled catheters were attributed to catheter replacement into a preexisting fibrin sheath [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized, controlled, pilot trial was conducted to investigate the impact of angioplasty sheath disruption on catheter patency and function [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/56\">",
"       56",
"      </a>",
"      ]. Forty-seven long-term hemodialysis patients with secondary, refractory catheter dysfunction underwent guidewire exchange to replace their catheters. Sheaths were present in 33 (70 percent) of the 47 patients. In 18 patients who were randomly assigned to disruption, the median time to repeat dysfunction was 373 days compared with 97.5 days in patients who did not undergo disruption (p = 0.22), and the median time to repeat catheter exchange was 411 and 198 days, respectively (p = 0.17). Fourteen patients had no sheaths, and their median times to repeat dysfunction and repeat exchange were 849 and 879 days, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Replacing the catheter can be performed using a technique that preserves both the exit and venotomy sites. Over-the-guidewire exchange of tunneled hemodialysis catheters is safe and easily accomplished. It causes no increase in infectious complications and provides similar catheter longevity to de novo catheter placement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, for example, 42 catheters were placed through the preexisting subcutaneous tunnels of failing catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/57\">",
"     57",
"    </a>",
"    ]. Technical success for catheter exchange was 93 percent. Infection rates were comparable to those of de novo catheter placement: 0.15 and 0.11 infections per 100 catheter days for de novo and exchanged catheters, respectively. Catheter duration of function was not significantly different for de novo and exchanged catheters: 63 and 51 percent at three months, 51 and 37 percent at six months, and 35 and 30 percent at 12 months, respectively.",
"   </p>",
"   <p>",
"    Catheter exchange is also an effective means of prolonging catheter patency in patients with end-stage renal disease and limited central venous access sites. This was illustrated in a study that evaluated the outcomes of 51 consecutive patients who underwent 88 catheter exchanges because of poor flow rates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/58\">",
"     58",
"    </a>",
"    ]. Catheter exchanges were performed through the existing subcutaneous tract over a guidewire. Life table analysis was performed to evaluate catheter patency rates after initial placement (primary patency) and after multiple exchanges (secondary patency). The technical success rate for hemodialysis catheter exchange was 100 percent. Primary catheter patency was 42 and 16 percent at 60 and 120 days, respectively, while secondary patency was 92 and 82 percent at 60 and 120 days. The cumulative infection rate was 1.1 per 1000 catheter days. There were no complications from the procedure.",
"   </p>",
"   <p>",
"    Advantages to catheter exchange are that the procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preserves the exit and venotomy site",
"     </li>",
"     <li>",
"      Is safe",
"     </li>",
"     <li>",
"      Is less expensive than fibrin sheath stripping (see below)",
"     </li>",
"     <li>",
"      Has a high rate of success",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A disadvantage of this technique is that a new catheter exit wound is created. However, this is not a significant problem. In the above study utilizing this technique, there was a cumulative infection rate of only 1.1 per 1000 catheter days and no reported bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Fibrin sheath stripping",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fibrin sheath can be stripped using a snare catheter. The snare is introduced through the femoral vein from where it is advanced up to the level of the dialysis catheter. The reported success of this procedure ranges from 75 to 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/40,59-63\">",
"     40,59-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported mean duration of primary patency following fibrin sheath stripping has been in the range of 12 to 126 days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/40,59-62\">",
"     40,59-62",
"    </a>",
"    ]. In one report, dialysis blood flow had dropped back to pretreatment levels by the fifth post-treatment dialysis session [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/40\">",
"     40",
"    </a>",
"    ]. In another, the 15-, 30-, and 45-day primary patency rates were 75 percent, 52 percent, and 35 percent, respectively. Although clinical pulmonary embolization has not been reported, fibrin sheath stripping generally does result in asymptomatic embolization of the sheath material [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technique of fibrin sheath stripping has been compared to other techniques. In a comparison with transcatheter urokinase infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/59\">",
"     59",
"    </a>",
"    ], no significant difference in primary patency of the treated catheters was noted. In a comparison with catheter exchange, cases treated by means of exchange were found to be significantly more likely to remain patent for up to four months than are those treated by means of stripping [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/62\">",
"     62",
"    </a>",
"    ]. In this study, mean catheter patency for the stripping and exchange group were 24.5",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    29.3 days and 52.2",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    43 days, respectively. After exchange, patency rates at one, two, three, and four months were 71, 33, 27, and 27 percent, respectively, compared to 31, 16, 7, and 0 percent after stripping, respectively.",
"   </p>",
"   <p>",
"    Additional disadvantages of the procedure are the cost of the snare, the additional discomfort of the patient, the increased duration of the procedure and the increased recovery time for the patient following a femoral vein cannulation. It does not appear that fibrin sheath stripping is a good technique. It should be",
"    <strong>",
"     abandoned.",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Summary and recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late-developing catheters malfunction due to thrombosis (whether extrinsic or intrinsic) is defined as the failure to attain and maintain an extracorporeal blood flow sufficient to perform hemodialysis without significantly lengthening the hemodialysis treatment in a catheter that was previously working adequately. Sufficient extracorporeal blood flow is considered to be 300",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    although the goal for optimal flow should be 400",
"    <span class=\"nowrap\">",
"     ml/min.",
"    </span>",
"   </p>",
"   <p>",
"    Once",
"    recognized, catheter malfunction should be addressed immediately. Treatment of intrinsic catheter-related thrombosis can be categorized as either primary (which can be immediately applied within the hemodialysis facility), or secondary (for which the patient has to be sent to referral facility):",
"   </p>",
"   <p>",
"    A forceful flush should be the",
"    <strong>",
"     first",
"    </strong>",
"    approach to treatment of a malfunctioning catheter that has previously functioned adequately. If this is ineffective, the instillation of tPA has been extremely useful to the nephrologist in managing catheter dysfunction within the dialysis facility. By comparison, the value of intraluminal lytic enzyme infusion is questionable and it is not recommended.",
"   </p>",
"   <p>",
"    If the problem cannot be successfully resolved within the dialysis facility or if the treatment applied does not have an effect of sufficient duration, then the case should be referred to a secondary treatment facility for radiographic evaluation. Appropriate treatment should then be based upon the findings of this evaluation. The most commonly encountered problem is the fibrin sheath.",
"   </p>",
"   <p>",
"    Catheter exchange over a guidewire can be effectively used to eliminate intrinsic catheter thrombosis and is the",
"    <strong>",
"     secondary",
"    </strong>",
"    &nbsp;",
"    <strong>",
"     treatment of choice",
"    </strong>",
"    for intrinsic catheter thrombosis. Prior to inserting the new catheter, the presence of a fibrin sheath should be determined. If present, it should be obliterated prior to the placement of the new catheter.",
"   </p>",
"   <p>",
"    By comparison, fibrin sheath stripping does not appear to be a good technique. It should be abandoned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the clinical consequences of catheter thrombus, the institution of measures aimed at preventing thrombus formation is a significant issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Measures performed immediately post-hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper flushing and locking the catheter with an appropriate anticoagulant following dialysis decreases the probability of thrombosis. As soon as the bloodline is disconnected from each side of the catheter, the catheter should be flushed with saline to remove any residual blood. This is done by connecting a 10-cc syringe filled with saline and performing as forcible a flush as possible. The catheter must then be clamped prior to removing the syringe to prevent blood from entering at the tip while the catheter is open.",
"   </p>",
"   <p>",
"    Each side of the chronic hemodialysis catheter has a fill volume inscribed on the clear portion of the catheter just below the cap. This volume is different for the two sides. The venous volume is generally 0.1 to 0.2 cc greater than the arterial volume.",
"   </p>",
"   <p>",
"    The fill-volume on a dialysis catheter can be associated with some adverse effects. There are reports of bleeding episodes after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    lock and antibiotic toxicity after antibiotic and anticoagulant combination lock:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 36 patients were evaluated: seven dialyzed through arteriovenous fistulas, 29 through in-dwelling venous catheters [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/64\">",
"       64",
"      </a>",
"      ]. To assess the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      lock, a full-dose heparin lock as well as a much weaker heparin lock and a citrate lock were used. Clotting from the patient group with arteriovenous fistulae was normal following dialysis. Patients with in-dwelling venous catheters and heparin locks had significantly deranged clotting; 6 out of 10 patients had abnormal APTT results. All patients with catheters, heparin-free dialysis, and heparin locks had deranged clotting (seven out of seven). The rate decreased significantly when heparinized saline was used as a lock. A subset of patients had a citrate lock rather than a heparin lock; the clotting results normalized in all but one patient.",
"     </li>",
"     <li>",
"      In a study designed to compare leakage for different brands of double lumen dialysis catheters, five different double lumen dialysis catheters were tested using three different lock volumes: the stated lock volume and both 20 percent over and under that volume [",
"      <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/65\">",
"       65",
"      </a>",
"      ]. All double lumen dialysis catheters tested had a substantial amount of leak when the catheter lock volume was used, and leak ratio increases significantly with 20 percent overfill. There was a leak even when using 20 percent less than the lock volume.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The phenomenon that results in this anomaly of leakage is shear stress as it relates to laminar flow in the catheter lumen. The stated fill volume for a catheter is measured under static conditions and incorrectly assumes that the advancing wave of introduced fluid moves as a vertical wall. Instead, the dynamics of shear stress dictate that there is a significant difference in velocity between the center of the column of advancing fluid and the boundary layer in contact with the wall where it is zero. Thus, the introduced fluid (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in this instance) moves down the catheter with a hyperbolic advancing edge. This results in leakage, although less than the amount of the lock volume.",
"   </p>",
"   <p>",
"    Limited evidence suggests that 4 percent citrate may be as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in reducing thrombosis. In a randomized pilot study of 61 hemodialysis patients, the incidence of thrombosis and catheter-associated bacteremia was similar with both locking agents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Systemic anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether there is a reliably effective means for preventing thrombi utilizing systemic anticoagulation, good controlled studies have not been reported. In patients with central venous catheters either to facilitate treatment of a hematologic malignancy or to administer parenteral nutrition, some studies have reported improved central venous catheter patency rates with 1 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , a dose without a discernible effect on the International Normalized Ratio (INR) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. However, in a randomized placebo-controlled trial, this sub-therapeutic approach was shown to not be effective in preventing thrombus formation with hemodialysis catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uncontrolled reports have reported benefits from anticoagulation at therapeutic levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. In a retrospective study of 221 patients with tunneled dialysis catheters, it was found that the thrombosis rate for patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    was 0.13 events per 100 catheter-days, while thrombosis rate for patients not taking warfarin was 0.03 events per 100 catheter-days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/70\">",
"     70",
"    </a>",
"    ]. Although it was not the focus of the study, the data from the study of mini-dose warfarin with dialysis catheters cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/69\">",
"     69",
"    </a>",
"    ] suggested improved catheter survival in patients with an INR greater than 1.00. In another study of patients with tunneled catheters that had been treated with lytic enzyme for thrombosis, it was reported that long-term patency was considerable enhanced by anticoagulation with warfarin. The authors of this study recommended carefully controlled anticoagulation to maintain the INR in the range of 2 to 2.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/71\">",
"     71",
"    </a>",
"    ]. Another study reported success in patients at high risk for thrombosis with the maintenance of target INR in the range of 1.5 to 2.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some centers have administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    utilizing a strategy in which the dose is titrated upwards in a stepwise manner until thrombotic episodes resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/49,73,74\">",
"     49,73,74",
"    </a>",
"    ]. With this protocol, the patient is begun on low dose warfarin (1",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    after the first episode of catheter malfunction. The dose is then raised with each subsequent episode until there is no recurrence. This results in varying degrees of systemic anticoagulation. In one study, the average dose of warfarin was 2.1 &plusmn; 1.6",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    which resulted in an average INR of 1.5 &plusmn; 0.9 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/22/15722/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in the absence of controlled prospective studies confirming the benefits of anticoagulation use in catheter patients, we",
"    <strong>",
"     cannot",
"    </strong>",
"    currently recommend its general use.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/1\">",
"      Little MA, O'Riordan A, Lucey B, et al. A prospective study of complications associated with cuffed, tunnelled haemodialysis catheters. Nephrol Dial Transplant 2001; 16:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/2\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/3\">",
"      Beathard GA. Catheter thrombosis. Semin Dial 2001; 14:441.",
"     </a>",
"    </li>",
"    <li>",
"     NKF-K/DOQI clinical practice guidelines for vascular access. Guideline.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/5\">",
"      Lund GB, Trerotola SO, Scheel PF Jr, et al. Outcome of tunneled hemodialysis catheters placed by radiologists. Radiology 1996; 198:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/6\">",
"      Suhocki PV, Conlon PJ Jr, Knelson MH, et al. Silastic cuffed catheters for hemodialysis vascular access: thrombolytic and mechanical correction of malfunction. Am J Kidney Dis 1996; 28:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/7\">",
"      Agraharkar M, Isaacson S, Mendelssohn D, et al. Percutaneously inserted silastic jugular hemodialysis catheters seldom cause jugular vein thrombosis. ASAIO J 1995; 41:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/8\">",
"      Karnik R, Valentin A, Winkler WB, et al. Duplex sonographic detection of internal jugular venous thrombosis after removal of central venous catheters. Clin Cardiol 1993; 16:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/9\">",
"      Aburahma AF, Sadler DL, Robinson PA. Axillary subclavian vein thrombosis. Changing patterns of etiology, diagnostic, and therapeutic modalities. Am Surg 1991; 57:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/10\">",
"      Diebold J, L&ouml;hrs U. Venous thrombosis and pulmonary embolism. A study of 5039 autopsies. Pathol Res Pract 1991; 187:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/11\">",
"      Horattas MC, Wright DJ, Fenton AH, et al. Changing concepts of deep venous thrombosis of the upper extremity--report of a series and review of the literature. Surgery 1988; 104:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/12\">",
"      Reed, J, Harman, JT, Harris, V. Regional fibrinolytic therapy for iatrogenic subclavian vein thrombosis. Seminars Interv Rad 1992; 9:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/13\">",
"      Little MA, Walshe JJ. A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction. Am J Kidney Dis 2002; 39:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/14\">",
"      Haire WD, Lynch TG, Lieberman RP, et al. Utility of duplex ultrasound in the diagnosis of asymptomatic catheter-induced subclavian vein thrombosis. J Ultrasound Med 1991; 10:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/15\">",
"      Haage P, Krings T, Schmitz-Rode T. Nontraumatic vascular emergencies: imaging and intervention in acute venous occlusion. Eur Radiol 2002; 12:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/16\">",
"      Male C, Chait P, Ginsberg JS, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost 2002; 87:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/17\">",
"      K&ouml;ksoy C, Kuzu A, Kutlay J, et al. The diagnostic value of colour Doppler ultrasound in central venous catheter related thrombosis. Clin Radiol 1995; 50:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/18\">",
"      Passman MA, Criado E, Farber MA, et al. Efficacy of color flow duplex imaging for proximal upper extremity venous outflow obstruction in hemodialysis patients. J Vasc Surg 1998; 28:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/19\">",
"      Haire WD, Lynch TG, Lund GB, et al. Limitations of magnetic resonance imaging and ultrasound-directed (duplex) scanning in the diagnosis of subclavian vein thrombosis. J Vasc Surg 1991; 13:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/20\">",
"      Sabeti S, Schillinger M, Mlekusch W, et al. Treatment of subclavian-axillary vein thrombosis: long-term outcome of anticoagulation versus systemic thrombolysis. Thromb Res 2002; 108:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/21\">",
"      Fuchs S, Pollak A, Gilon D. Central venous catheter mechanical irritation of the right atrial free Wall:A cause for thrombus formation. Cardiology 1999; 91:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/22\">",
"      Forauer AR, Theoharis C. Histologic changes in the human vein wall adjacent to indwelling central venous catheters. J Vasc Interv Radiol 2003; 14:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/23\">",
"      Kohler TR, Kirkman TR. Central venous catheter failure is induced by injury and can be prevented by stabilizing the catheter tip. J Vasc Surg 1998; 28:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/24\">",
"      Ghani MK, Boccalandro F, Denktas AE, Barasch E. Right atrial thrombus formation associated with central venous catheters utilization in hemodialysis patients. Intensive Care Med 2003; 29:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/25\">",
"      Ram R, Swarnalatha G, Rakesh Y, et al. Right atrial thrombus due to internal jugular vein catheter. Hemodial Int 2009; 13:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/26\">",
"      Negulescu O, Coco M, Croll J, Mokrzycki MH. Large atrial thrombus formation associated with tunneled cuffed hemodialysis catheters. Clin Nephrol 2003; 59:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/27\">",
"      Rotellar C, Sims SC, Freeland J, et al. Right atrium thrombosis in patients on hemodialysis. Am J Kidney Dis 1996; 27:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/28\">",
"      Kingdon EJ, Holt SG, Davar J, et al. Atrial thrombus and central venous dialysis catheters. Am J Kidney Dis 2001; 38:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/29\">",
"      Abid Q, Price D, Stewart MJ, Kendall S. Septic pulmonary emboli caused by a hemodialysis catheter. Asian Cardiovasc Thorac Ann 2002; 10:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/30\">",
"      Shah A, Murray M, Nzerue C. Right atrial thrombi complicating use of central venous catheters in hemodialysis. Int J Artif Organs 2004; 27:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/31\">",
"      Rose PS, Punjabi NM, Pearse DB. Treatment of right heart thromboemboli. Chest 2002; 121:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/32\">",
"      Dinckal MH, Davutoglu V, Soydinc S, et al. Large thrombus at the site of primary sutured atrial septal defect associated with pulmonary embolism and treatment by thrombolysis. Echocardiography 2003; 20:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/33\">",
"      Cesaro S, Paris M, Corr&ograve; R, et al. Successful treatment of a catheter-related right atrial thrombosis with recombinant tissue plasminogen activator and heparin. Support Care Cancer 2002; 10:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/34\">",
"      Mezzani A, Bielli M, Zanetta M. Thrombolytic treatment of type A right atrial thrombi: description of three cases and review of the literature. G Ital Cardiol 1999; 29:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/35\">",
"      Janssens U, Breithardt OA, Greinacher A. Successful thrombolysis of right atrial and ventricle thrombi encircling a temporary pacemaker lead in a patient with heparin-induced thrombocytopenia type II. Pacing Clin Electrophysiol 1999; 22:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/36\">",
"      Hoshal VL Jr, Ause RG, Hoskins PA. Fibrin sleeve formation on indwelling subclavian central venous catheters. Arch Surg 1971; 102:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/37\">",
"      Xiang DZ, Verbeken EK, Van Lommel AT, et al. Composition and formation of the sleeve enveloping a central venous catheter. J Vasc Surg 1998; 28:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/38\">",
"      O'Farrell L, Griffith JW, Lang CM. Histologic development of the sheath that forms around long-term implanted central venous catheters. JPEN J Parenter Enteral Nutr 1996; 20:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/39\">",
"      Grossi C, Mangano S, Zani MB, et al. Tesio catheters: findings in post-mortem examination. Nephrol Dial Transplant 1996; 11:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/40\">",
"      Haskal ZJ, Leen VH, Thomas-Hawkins C, et al. Transvenous removal of fibrin sheaths from tunneled hemodialysis catheters. J Vasc Interv Radiol 1996; 7:513.",
"     </a>",
"    </li>",
"    <li>",
"     NKF-K/DOQI: Clinical Practice Guidelines For Vascular Access: Update 2006. Clinical Practice Guideline 7: Prevention and treatment of catheter and port complications, 7.1 catheters and ports should be evaluated when they become dysfunctional.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/42\">",
"      Eyrich H, Walton T, Macon EJ, Howe A. Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis. Am J Health Syst Pharm 2002; 59:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/43\">",
"      Haire WD, Atkinson JB, Stephens LC, Kotulak GD. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost 1994; 72:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/44\">",
"      Zacharias JM, Weatherston CP, Spewak CR, Vercaigne LM. Alteplase versus urokinase for occluded hemodialysis catheters. Ann Pharmacother 2003; 37:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/45\">",
"      Clase CM, Crowther MA, Ingram AJ, Cin&agrave; CS. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review. J Thromb Thrombolysis 2001; 11:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/46\">",
"      Hilleman DE, Dunlay RW, Packard KA. Reteplase for dysfunctional hemodialysis catheter clearance. Pharmacotherapy 2003; 23:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/47\">",
"      Deitcher SR, Fesen MR, Kiproff PM, et al. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 2002; 20:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/48\">",
"      Ponec D, Irwin D, Haire WD, et al. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001; 12:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/49\">",
"      Twardowski, ZJ. Stepwise anticoagulation with warfarin for prevention of intravenous catheter thrombosis. Hemodial Int 2000; 4:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/50\">",
"      Tumlin J, Goldman J, Spiegel DM, et al. A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3. Clin J Am Soc Nephrol 2010; 5:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/51\">",
"      Twardowski ZJ. The clotted central vein catheter for haemodialysis. Nephrol Dial Transplant 1998; 13:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/52\">",
"      Shaffer D. Catheter-related sepsis complicating long-term, tunnelled central venous dialysis catheters: management by guidewire exchange. Am J Kidney Dis 1995; 25:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/53\">",
"      Savader SJ, Ehrman KO, Porter DJ, et al. Treatment of hemodialysis catheter-associated fibrin sheaths by rt-PA infusion: critical analysis of 124 procedures. J Vasc Interv Radiol 2001; 12:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/54\">",
"      Onder AM, Chandar J, Saint-Vil M, et al. Catheter survival and comparison of catheter exchange methods in children on hemodialysis. Pediatr Nephrol 2007; 22:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/55\">",
"      Wong JK, Sadler DJ, McCarthy M, et al. Analysis of early failure of tunneled hemodialysis catheters. AJR Am J Roentgenol 2002; 179:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/56\">",
"      Oliver MJ, Mendelssohn DC, Quinn RR, et al. Catheter patency and function after catheter sheath disruption: a pilot study. Clin J Am Soc Nephrol 2007; 2:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/57\">",
"      Duszak R Jr, Haskal ZJ, Thomas-Hawkins C, et al. Replacement of failing tunneled hemodialysis catheters through pre-existing subcutaneous tunnels: a comparison of catheter function and infection rates for de novo placements and over-the-wire exchanges. J Vasc Interv Radiol 1998; 9:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/58\">",
"      Garofalo RS, Zaleski GX, Lorenz JM, et al. Exchange of poorly functioning tunneled permanent hemodialysis catheters. AJR Am J Roentgenol 1999; 173:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/59\">",
"      Gray RJ, Levitin A, Buck D, et al. Percutaneous fibrin sheath stripping versus transcatheter urokinase infusion for malfunctioning well-positioned tunneled central venous dialysis catheters: a prospective, randomized trial. J Vasc Interv Radiol 2000; 11:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/60\">",
"      Johnstone RD, Stewart GA, Akoh JA, et al. Percutaneous fibrin sleeve stripping of failing haemodialysis catheters. Nephrol Dial Transplant 1999; 14:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/61\">",
"      Brady PS, Spence LD, Levitin A, et al. Efficacy of percutaneous fibrin sheath stripping in restoring patency of tunneled hemodialysis catheters. AJR Am J Roentgenol 1999; 173:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/62\">",
"      Merport M, Murphy TP, Egglin TK, Dubel GJ. Fibrin sheath stripping versus catheter exchange for the treatment of failed tunneled hemodialysis catheters: randomized clinical trial. J Vasc Interv Radiol 2000; 11:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/63\">",
"      Crain MR, Mewissen MW, Ostrowski GJ, et al. Fibrin sleeve stripping for salvage of failing hemodialysis catheters: technique and initial results. Radiology 1996; 198:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/64\">",
"      Pepper RJ, Gale DP, Wajed J, et al. Inadvertent postdialysis anticoagulation due to heparin line locks. Hemodial Int 2007; 11:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/65\">",
"      Sungur M, Eryuksel E, Yavas S, et al. Exit of catheter lock solutions from double lumen acute haemodialysis catheters--an in vitro study. Nephrol Dial Transplant 2007; 22:3533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/66\">",
"      Macrae JM, Dojcinovic I, Djurdjev O, et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clin J Am Soc Nephrol 2008; 3:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/67\">",
"      Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/68\">",
"      Boraks P, Seale J, Price J, et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 1998; 101:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/69\">",
"      Mokrzycki MH, Jean-Jerome K, Rush H, et al. A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int 2001; 59:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/70\">",
"      Lee O, Raque JD, Lee LJ, et al. Retrospective assessment of risk factors to predict tunneled hemodialysis catheter outcome. J Vasc Interv Radiol 2004; 15:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/71\">",
"      Webb A, Abdalla M, Russell GI. A protocol of urokinase infusion and warfarin for the management of the thrombosed haemodialysis catheter. Nephrol Dial Transplant 2001; 16:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/72\">",
"      Zellweger M, Bouchard J, Raymond-Carrier S, et al. Systemic anticoagulation and prevention of hemodialysis catheter malfunction. ASAIO J 2005; 51:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/73\">",
"      Pierratos A. Nocturnal home haemodialysis: an update on a 5-year experience. Nephrol Dial Transplant 1999; 14:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/22/15722/abstract/74\">",
"      Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998; 9:859.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1906 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15722=[""].join("\n");
var outline_f15_22_15722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY CATHETER FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LATE CATHETER DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Extrinsic catheter-related thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Axillo-subclavian vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H35800822\">",
"      Symptomatic",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H35800829\">",
"      - Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H35800836\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H35800857\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Mural thrombus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Intra-atrial thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intrinsic catheter-related thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intraluminal thrombus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Catheter tip thrombus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Fibrin sheath thrombus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT OF LATE DEVELOPING FLOW PROBLEMS DUE TO INTRINSIC THROMBUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Primary treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Forceful saline flush",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Intraluminal lytic enzyme",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Infusion of lytic enzyme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Secondary treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Catheter exchange over a guidewire",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Fibrin sheath stripping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Summary and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Measures performed immediately post-hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Systemic anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=related_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16727?source=related_link\">",
"      Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7942?source=related_link\">",
"      Strategies other than treatment of stenosis to prevent thrombosis of hemodialysis vascular access grafts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_22_15723="Storage iron pool";
var content_f15_22_15723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distribution of body iron in men and women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"50%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        70 kg man",
"       </td>",
"       <td class=\"subtitle1\">",
"        60 kg woman",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron stores - transferrin, ferritin, hemosiderin",
"       </td>",
"       <td>",
"        0.7 g",
"       </td>",
"       <td>",
"        0.3 g*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin",
"       </td>",
"       <td>",
"        2.5 g",
"       </td>",
"       <td>",
"        1.9 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myoglobin",
"       </td>",
"       <td>",
"        0.14 g",
"       </td>",
"       <td>",
"        0.13 g",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Heme enzymes",
"       </td>",
"       <td>",
"        0.01 g",
"       </td>",
"       <td>",
"        0.01 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         TOTAL",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         3.35 g",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.34 g",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * This value is an average. Approximately 20 percent of menstruant women have no iron stores.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Schrier SL, Scientific American Medicine, Scientific American, New York, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15723=[""].join("\n");
var outline_f15_22_15723=null;
var title_f15_22_15724="ACC AHA Rx refractory HF";
var content_f15_22_15724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Management of refractory end-stage heart failure (HF, stage D)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following approaches are effective for management of patients with end-stage HF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Referral to an HF program with expertise in this problem.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Careful control of fluid status.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Referral for cardiac transplantation if potentially eligible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Options for end-of-life care should be discussed with patient and family.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Patients with an implantable cardioverter-defibrillator should be informed about the option of inactivating the device.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following approach in patients with end-stage HF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; A left ventricular assist device as permanent or \"destination\" therapy in highly selected patients with an estimated one-year mortality exceeding 50 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of the following approaches in patients with end-stage HF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Placement of a pulmonary artery catheter as a guide to therapy if persistent severe symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Mitral valve surgery (repair or replacement) for severe secondary mitral regurgitation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Continuous intravenous infusion of an inotropic agent for palliation of symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that the following approaches are not useful or may be harmful in patients with end-stage HF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Partial left ventriculectomy in nonischemic cardiomyopathy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Routine intermittent infusions of vasoactive and positive inotropic agents.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15724=[""].join("\n");
var outline_f15_22_15724=null;
var title_f15_22_15725="Measures RR variability";
var content_f15_22_15725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definitions for time and frequency domain measures of heart period variability",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Units",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Time Domain - Statistical measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Night-day difference",
"       </td>",
"       <td>",
"        ms",
"       </td>",
"       <td>",
"        Difference between the average of all the normal RR intervals at night (24:00 to 05:00) and the average of all the normal RR intervals during the day (07:30 to 21:30).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SDNN",
"       </td>",
"       <td>",
"        ms",
"       </td>",
"       <td>",
"        Standard deviation of all normal RR intervals in the entire 24-hour ECG recording.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SDANN",
"       </td>",
"       <td>",
"        ms",
"       </td>",
"       <td>",
"        Standard deviation of the average normal RR intervals for all 288 5-minute segments of a 24-hour ECG recording (each average is weighted by the fraction of the 5 minutes that has normal RR intervals).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ASDNN",
"       </td>",
"       <td>",
"        ms",
"       </td>",
"       <td>",
"        Average of the standard deviations of normal RR intervals for all 288 5-minute segments of a 24-hour EGC recording.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        r-MSSD",
"       </td>",
"       <td>",
"        ms",
"       </td>",
"       <td>",
"        Root mean square successive difference, the square root of",
"the mean of the squared differences between adjacent normal RR",
"intervals over the entire 24-hour ECG recording.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        pNN50",
"       </td>",
"       <td>",
"        percent",
"       </td>",
"       <td>",
"        Percent of differences between adjacent normal RR intervals",
"that are greater than 50 ms computed over the entire 24-hour ECG",
"recording.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        NN50",
"       </td>",
"       <td>",
"        none",
"       </td>",
"       <td>",
"        Number of adjacent normal RR intervals that are greater than 50 ms counted over the entire 24-hour ECG recording.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Time Domain - Geometric measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HRV triangular index",
"       </td>",
"       <td>",
"        none",
"       </td>",
"       <td>",
"        Total number of NN intervals divided by the number of NN",
"intervals in the modal bin of a histogram of all NN intervals with a",
"bin width of 7.8125 msec (for a sampling rate of 128/sec).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TINN",
"       </td>",
"       <td>",
"        msec",
"       </td>",
"       <td>",
"        Baseline width of the minimum square difference triangular",
"interpolation of the highest peak of the histogram of all NN intervals.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Frequency Domain Measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Total power",
"       </td>",
"       <td>",
"        ms",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        The energy in the heart period power spectrum up to 0.40 Hz.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ultra low frequency (ULF) power",
"       </td>",
"       <td>",
"        ms",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        The energy in the heart period power spectrum up to 0.0033 Hz.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Very low frequency (VLF) power",
"       </td>",
"       <td>",
"        ms",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        The energy in the heart period power spectrum between 0.0033 and 0.04 Hz.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low frequency (LF) power",
"       </td>",
"       <td>",
"        ms",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        The energy in the heart period power spectrum between 0.04 and 0.15 Hz.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High frequency (HF) power",
"       </td>",
"       <td>",
"        ms",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        The energy in the heart period power spectrum between 0.15 and 0.40 Hz.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LF/HF ratio",
"       </td>",
"       <td>",
"        none",
"       </td>",
"       <td>",
"        THe ratio of low to high frequency power.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        beta",
"       </td>",
"       <td>",
"        none",
"       </td>",
"       <td>",
"        Slope of log (power) on log (frequency) between 0.01 and 0.0001 Hz on a log-log plot.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15725=[""].join("\n");
var outline_f15_22_15725=null;
var title_f15_22_15726="Venous Doppler waveforms";
var content_f15_22_15726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Shown is a diagrammatic representation of a venous flow velocity waveform",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 318px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The triphasic waveform (S: systole, D: diastole, a: atrial contraction) reflects volume flow changes during the cardiac cycle. The fourth phase is the v-descent, corresponding to the period of end of ventricular systole just before the atrioventricular valves open.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_22_15726=[""].join("\n");
var outline_f15_22_15726=null;
var title_f15_22_15727="Contents: Immunodeficiency states non HIV";
var content_f15_22_15727=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/1/44061\">",
"       Allergy and Immunology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Immunodeficiency states non HIV",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Immunodeficiency states non HIV",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antibody deficiencies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/52/21321\">",
"           Agammaglobulinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/28/17866\">",
"           Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/45/38617\">",
"           Common variable immunodeficiency in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/32/21001\">",
"           Hyperimmunoglobulin M syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/60/13258\">",
"           IgG subclass deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/16/35078\">",
"           IgG subclasses: Physical properties, genetics, and biologic functions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/32/38409\">",
"           Intravenous immune globulin: Adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/29/9688\">",
"           Pathogenesis of common variable immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/48/24326\">",
"           Primary humoral immune deficiencies: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/63/24570\">",
"           Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/17/30998\">",
"           Selective IgA deficiency: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/44/38597\">",
"           Selective IgE deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/11/42168\">",
"           Selective IgM deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/51/17209\">",
"           Selective antibody deficiency with normal immunoglobulins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/47/30457\">",
"           Treatment and prognosis of common variable immunodeficiency",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chromosomal breakage syndromes associated with immunodeficiency",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/60/23497\">",
"           Ataxia-telangiectasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/42/35493\">",
"           Bloom syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/27/439\">",
"           Nijmegen breakage syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Combined immunodeficiency",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/27/2488\">",
"           Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/43/27320\">",
"           Adenosine deaminase deficiency: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/42/28329\">",
"           CD3/T cell receptor complex disorders causing immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/58/40873\">",
"           Combined immunodeficiencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/2/25637\">",
"           Purine nucleoside phosphorylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/52/15176\">",
"           Severe combined immunodeficiency (SCID) with JAK3 deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/30/42471\">",
"           Severe combined immunodeficiency (SCID): An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/0/10\">",
"           Severe combined immunodeficiency (SCID): Specific defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/56/20362\">",
"           T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/26/25001\">",
"           T cell receptor signaling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/18/1316\">",
"           X-linked severe combined immunodeficiency (SCID)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/2/42022\">",
"           ZAP-70 deficiency",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Immunodeficiency disorders - General considerations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/26/43433\">",
"           Approach to the adult with recurrent infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/47/30458\">",
"           Approach to the child with recurrent infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/48/24328\">",
"           Assessing the immunologic response to vaccination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/6/23656\">",
"           Flow cytometry for the diagnosis of primary immunodeficiencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/51/33590\">",
"           Gene therapy for primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/2/1066\">",
"           Hematopoietic cell transplantation for primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/48/27401\">",
"           Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/52/15178\">",
"           Immune function in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/48/14087\">",
"           Immune globulin therapy in primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/58/43945\">",
"           Laboratory evaluation of the immune system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8633\">",
"           Medical management of immune deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/9/31896\">",
"           Subcutaneous and intramuscular immune globulin therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/5/37978\">",
"           Pulmonary complications of primary immunodeficiencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/22/40295\">",
"           Syndromic immunodeficiencies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other well defined immunodeficiency syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/36/30279\">",
"           Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/58/30629\">",
"           Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/15/246\">",
"           Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/51/7992\">",
"           Cartilage-hair hypoplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/1/22553\">",
"           Chronic mucocutaneous candidiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/12/22729\">",
"           DiGeorge syndrome: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/37/32343\">",
"           DiGeorge syndrome: Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/15/15608\">",
"           DiGeorge syndrome: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/25/32153\">",
"           Hyperimmunoglobulin E syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/15/25850\">",
"           IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/19/30009\">",
"           Idiopathic CD4+ lymphocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/26/426\">",
"           Idiopathic systemic capillary leak syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/8/12420\">",
"           Mannose-binding lectin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/14/19690\">",
"           Mannose-binding lectin deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/12/4297\">",
"           Mendelian susceptibility to mycobacterial diseases (MSMD)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/10/30889\">",
"           NK cell deficiency syndromes: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/39/4724\">",
"           NK cell deficiency syndromes: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/29/36313\">",
"           Wiskott-Aldrich syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/38/33384\">",
"           X-linked lymphoproliferative disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Phagocyte disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/54/29542\">",
"           Acquired disorders of the complement system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/18/42278\">",
"           Chediak-Higashi syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/36/10826\">",
"           Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/12/11465\">",
"           Chronic granulomatous disease: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/22/24937\">",
"           Congenital neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42966\">",
"           Cyclic neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/41/17048\">",
"           Determinants of neutrophil movement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/33/42520\">",
"           Immune neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/58/42920\">",
"           Inherited disorders of the complement system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/26/22953\">",
"           Leukocyte adhesion deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/60/14280\">",
"           Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/37/10838\">",
"           Neutrophil-specific granule deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/25/10647\">",
"           Overview and clinical assessment of the complement system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/47/18170\">",
"           Overview of neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43620\">",
"           Primary disorders of phagocytic function: An overview",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Secondary immunodeficiency",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/24/7561\">",
"           Secondary immune deficiency due to miscellaneous causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/0/29706\">",
"           Secondary immune deficiency induced by drugs and biologics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/59/38842\">",
"           Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-9F3545D60F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f15_22_15727=[""].join("\n");
var outline_f15_22_15727=null;
